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Pharmaceutical care planning is increasingly seen as the most effective manner by 
which to deliver pharmaceutical care services to the patient. The role of the 
pharmacist, both specialist and generalist, is paramount, as much of the treatment in 
Mental Health is dependent on the effective management of the patients 
medication(1). Consequently, there is a need for standardised pharmaceutical care 
planning within the speciality. In Scotland, the Mental Health Pharmacy Strategy 
Group (MHPSG) commissioned a project to develop and implement a care plan 
document that could be used at a national level. This project has taken on the 
recommendations from that study to re-design and validate a standardised document 
for pharmaceutical care planning in a psychiatric in-patient population. 
Methods 
Recommendations from the MHPSG‟s study and candidate care issues specific to 
mental health pharmacy were identified and incorporated into the re-design of the 
care plan document. A small field test was then conducted in NHS Lothian, where 12 
care plans were completed by six pharmacists. Feedback from this study was used to 
re-develop a 2nd draft, which was subjected to peer review and assessment by focus 
group discussion. The focus group consisted of clinical mental health pharmacists 
from different health board areas who discussed the content, layout and general 
utility of the document. Findings from this discussion informed the re-development of 
a final version of the care plan document. 
Results 
A four page standardised document that will enable a uniform care planning 
approach within mental health pharmacy.   
Conclusion 
The development of a national care planning system is a labour intensive process. 
This project has managed to produce a care plan that may be used as a standard 
within mental health in-patients after further validation. Whilst the majority of 
pharmacists are aware of its benefits, several issues became apparent which may 
impede its implementation and use.   
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“Mental health” and “mental illness” are not polar opposites, but may be thought of as 
points on a continuum(2). 
Mental health is a state of successful performance of mental function, resulting in 
complete mental and social well-being in which the individual can cope with the 
normal stresses of life, deals with family and interpersonal relationships, and 
contribute to community or society. Mental health refers to the successful 
performance of mental functions in terms of thought, mood, and behaviour.(2, 3) 
Mental illness is the term that refers collectively to all diagnosable mental disorders. It 
can be seen as a breakdown of the mental health, characterised by alterations in 
thinking, mood, or behaviour (or a combination of that) associated with distress 
and/or impaired functioning. Mental disorders are those health conditions in which 
alterations in mental functions are paramount.(2) 
1.1. Magnitude of Mental Health Problems 
Research suggests that about one in four people experience mental distress at any 
one time, with the most common problems being anxiety and depression. However, 
more serious conditions, such as schizophrenia, are also common, with one in every 
hundred people in the UK diagnosed with the condition. The UK spends about 10% 
of the total health budget on mental health.(4)  
Mental health problems also often complicate other diseases and occur twice as 
often in people with physical illness as in the general population. Episodes of mental 
illness can come and go throughout a person‟s life and some people may experience 
their mental illness only once and then fully recover. Mental illness is a general term 
that refers to a group of illnesses that affect the brain, and can be mild or severe, 
temporary or prolonged, but are usually treatable. Recovery rates for mental health 
problems are between 70% and 80%.(5, 6) 
Although as many as one in four people experience a mental health problem, and 
nearly three-quarters know someone who has been diagnosed with one, stigma has 
an important role within mental health practice. In spite of dramatic advances in our 
understanding and approach to mental ill health, some people still cling to the idea 
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that the straitjacket and the asylum are the norm. Stigma is often defined as „a mark 
of discredit or shame‟. The shame of having a mental health problem is so high that 
many who develop a mental health problem do not want anybody to know about it. 
Stigma is manifested by bias, distrust, stereotyping, fear, embarrassment, anger, 
and/or avoidance. In 2001 an „SEE ME...‟ campaign was initiated throughout 
Scotland to try and stop the stigma of mental illness. It has been a successful 
campaign, but as they have not met their goals yet, it is still running on its seventh 
year.(7, 8) 
1.1.1 Mental health disorders 
Definitions, assessments, and classifications of mental disorders can vary, but 
guideline criterion listed in the International Classification of Diseases (ICD10) and 
the (American Psychiatric Association) Diagnostic and Statistical Manual of Mental 
Disorders (DSM IV) are widely accepted by mental health professionals. Categories 
of diagnoses in these schemes may include mood disorders, anxiety disorders, 
psychotic disorders, eating disorders, developmental disorders and personality 
disorders. This text will give some more information on mood and psychotic 
disorders, as they make up the highest number of admissions to hospital. According 
to a survey done for adult psychiatric illness in England, depression and anxiety was 
the most common reason for hospital admission, accounting for 29.6% of all 
admissions, and schizophrenia and related psychoses came second as they 
accounted for 26.0% of the admissions(9). 
1.1.1.1. Mood disorders 
Mood disorders include depression, elation or a combination of the two. The primary 
affective disorders are classified as either unipolar or bipolar disorder. The exact 
aetiology is unknown, which is the case for most psychiatric disorders.(5) 
Unipolar disorder includes subtypes like major depression, chronic mild depression 
(dysthymia) and postpartum depression. Depression is the most common of the 
affective disorders as 17% of the population suffers from depression some time in 
their life(6). It is characterized by a low mood, loss of motivation, low self-esteem and 
diminished ability to experience pleasure.(6, 10) 
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Bipolar disorder appear in 1.3% of the population(6), and includes subtypes like 
bipolar I, bipolar II and cyclothymia. The disorder causes unusual shifts in a person‟s 
mood, energy, and ability to function, and is described by alternating periods of 
mania and depression. Bipolar I disorder is characterized by full manic episodes and 
major depressive episodes, while bipolar II has hypomanic and major depressive 
episodes. Cyclothymia is a milder form of bipolar disorder where the episodes of 
depression never meet the criteria for major depression. It is enough with only one 
manic episode to diagnose bipolar disorder, but depression is inevitable later in the 
course of the illness. The onset of mania is usually sudden and dramatic, and the 
patient often resists treatment because they don‟t recognize that they are ill. 
Episodes of illness are associated with distress and disruption, and a relatively high 
risk of suicide.(5, 6, 10) 
1.1.1.2. Psychotic disorders 
Psychotic disorders include schizophrenia and delusional disorder. Schizoaffective 
disorder is a category used for individuals showing aspects of both schizophrenia and 
affective (mood) disorders. Delusional disorder involves holding one or more non-
bizarre delusions in the absence of any other significant signs or symptoms of mental 
illness (previously called paranoia).(6) 
Schizophrenia is a chronic, severe and disabling brain disorder with a great range of 
symptoms. It is not to be mistaken with split personality. It affects about 1% of the 
population and is one of the most important forms of psychiatric illnesses, as it affects 
young people and is often chronic. The illness usually has positive symptoms like 
delusions, hallucinations and thought disorder; negative symptoms like apathy, social 
withdrawal and lack of drive; and cognitive symptoms which can be problems with 
attention, memory and ability to plan and organise.(6, 10-12) 
The cause of schizophrenia is unclear, but the mode of action of antipsychotic drugs 
has led us to believe that it is caused by an alternation in the level of dopamine 
activity in the brain. Drugs that decrease the dopamine level seem to be effective, 
while drugs that increase the dopamine level can induce psychosis or exacerbate a 
schizophrenic illness(11).  




For the purposes of this report, the main psychotropic drugs are discussed. These 
are: antidepressants, antipsychotics and mood stabilisers. 
1.1.2.1. Antidepressant medication 
Antidepressants are mostly used in patients that suffer from depression, and can be 
divided into tricyclic antidepressant (TCA), monoamine-oxidase inhibitors (MAOI) and 
selective serotonin re-uptake inhibitors (SSRI). According to systematic reviews and 
meta-analyses of studies undertaken in primary care and outpatient settings, all the 
different antidepressants have similar effectiveness in the majority of patients with 
major depressions(13). SSRIs are better tolerated than older TCAs (which are 
associated with higher incidences of anticholinergic side-effects, sedation, weight 
gain and cardiovascular complications), are safer in overdose and are more likely to 
be prescribed at recommended doses for an adequate period. MAOIs are also 
associated with a lot of undesirable side effects, and are therefore reserved for 
resistant depression. Considerations to take into account when selecting an 
antidepressant is previous response, side-effects, contraindications, toxicity in 
overdose, patient preference and clinician familiarity. (6, 10, 11, 13) 
In order to produce a full response the drugs are to be taken in adequate doses for 
about 4-6 weeks, and treatment should be continued for at least six months at full 
therapeutic dose before attempting withdrawal. Stopping and switching 
antidepressant can lead to „drug discontinuation syndrome‟ if it‟s not done gradually. 
Typical symptoms of antidepressant discontinuation syndrome include flu-like 
symptoms, insomnia, nausea, imbalance, sensory disturbances, and hyperarousal. 
These symptoms are usually mild, last one to two weeks, and are rapidly 
extinguished with reinstitution of antidepressant medication. Successful treatment 
with antidepressants should be reduced over a period of at least 4 weeks.(11, 13) 
1.1.2.2. Antipsychotic medication 
Antipsychotic drugs are a group of drugs commonly, but not exclusively, used to treat 
psychosis. Common conditions in which antipsychotics might be used include 
schizophrenia, bipolar disorder, mania and delusional disorder. The drugs are divided 
into the originally developed drugs, named classical or typical antipsychotics, and the 
more recently developed drugs, named atypical antipsychotics.  
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Patients may respond differently to different antipsychotic drugs, and often several 
drugs must be tried before the right one is found. This is mainly because of the wide 
range of side-effects that may occur. The antipsychotic potency of most 
antipsychotics is directly proportional to their ability to block dopamine receptors in 
the brain, although the exact mechanism is believed to be more complicated. Their 
selectivity for dopamine receptors varies a lot, and many also have significant effects 
on acetylcholine, norepinephrine, histamine and serotonin pathways. This gives the 
reason to expect a wide range of side-effects. The most common ones are; 
extrapyramidal side effects (EPS), such as rigidity, persistent muscle spasms, 
tremors, and restlessness; hyperprolactinaemia; reduced seizure threshold; postural 
hypotension; anticholinergic side-effects, such as dry mouth, blurred vision and 
constipation; weight gain and metabolic changes that is associated with an increased 
risk of developing hypertension, cardiovascular disease, type 2 diabetes and 
dyslipidaemia; and neuroleptic malignant syndrome (NMS), where the main 
symptoms are mild fever, fluctuating consciousness, muscular rigidity, autonomic 
instability and severe EPSEs (14).  
The „atypical‟ drugs have shown in clinical trials to have minimal potential for causing 
EPS. „Atypical‟ drugs are therefore better tolerated in normal clinical doses than 
„typical‟ drugs, and are recommended for first line use. (11, 15)  
Clozapine was the first „atypical‟ drug on the market and has shown to be very 
effective, but because of the significant risk of agranulocytosis is it largely reserved 
for use in treatment resistant patients. Agranulocytosis is an acute condition 
involving a severe and dangerous reduction in the number of white blood cells in 
the body. As the principal function of white cells is to combat infection, a decrease 
in the number of these cells can place patients at increased risk for infections. If 
the patient is on clozapine, a full blood count needs to be done weekly for 18 weeks, 
fortnightly until 52 weeks of treatment and then monthly thereafter if haematologically 
stable. To ensure that these tests are done, is clozapine only available through a 
distribution system, this means all results are authorised before medication is 
delivered/dispensed to the patient. (11, 12, 14) 
Other commonly used atypical drugs are sulpiride, amisulpiride, risperidone, 
olanzapine and quetiapine, which do not have the risks of agranulocytosis, like 
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clozapine, or EPS, like the „typical‟ drugs, but they can cause weight gain and 
metabolic changes (12). 
1.1.2.3. Mood stabilizers 
These agents are used to stabilise mood and so can be used to dampen an 
abnormally high mood (hypomania) or help to lift low mood (depression). 
Nevertheless, an antidepressant is often prescribed in addition to the mood stabilizer 
during depressive phases. This brings some risks as antidepressants can induce 
mania, psychosis, and other disturbing problems in bipolar patients - particularly 
when taken alone, but sometimes even when used with a mood stabilizer. (6, 11, 14) 
The first mood stabiliser on the marked and still the one most commonly used is 
lithium. It acts to control mania as well as depression, but is mainly used 
prophylactically in bipolar disorder (16). Its use in the treatment of acute mania is 
limited by the fact that it usually takes at least a week to achieve response because 
of its long plasma half-life. It can also be difficult to rapidly achieve therapeutic serum 
levels because of its narrow therapeutic window (approximately 0.6-1.0 mmol/L). If 
the plasma levels rise above 2.0 mmol/L, increased disorientation and seizures can 
occur, and that can progress to coma and death. This make monitoring essential, 
especially in the presence of a renal disease since lithium is excreted renally. The 
serum level should be measured after seven days, and then one week after each 
dose change until desired level has been achieved. Once the serum level is stable it 
should be checked every third month. Some studies have suggested a risk of birth 
defects in the new-born if a mother is taking lithium during her pregnancy. There is 
also evidence that sudden discontinuation of lithium increases the risk of a manic or 
hypomanic relapse, so if the treatment is to be stopped, it is advised to do it 
gradually.(6, 10, 11, 14, 16, 17) 
Other commonly drugs used as mood stabilisers are sodium valproate and 
carbamazepine. Both were first used for the management of epilepsy, but they have 
also been found to offer benefits to many bipolar patients (18). Sodium valproate has 
been found to be effective in patients who predominantly suffer with depression, 
whilst carbamazepine works less well in such cases (19). Like lithium, they need to be 
monitored and blood tests may be necessary, although monitoring often does not 
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have to be as strict as in the case of lithium. They also present some risks during 
pregnancy.(6, 11, 14, 19) 
 
1.2. Pharmaceutical care 
The concept of pharmaceutical care was developed in the United States by Douglas 
Hepler and Linda Strand in 1990. They defined it as “the responsible provision of 
drug therapy for the purpose of achieving definite outcomes that improve a patient’s 
quality of life” (20). This was subsequently refined by Strand and co-workers to “a 
practice in which the practitioner takes responsibility for a patient’s drug related 
needs and holds him or herself accountable for meeting these needs” (21). In order to 
achieve this, the practitioner needs to assess the patient to make sure the medicines 
taken is appropriate, safe and effective, and that the patient is able and willing to take 
the medication as intended. The practitioner also needs to develop a care plan for 
the patient and have a follow-up evaluation on a systematic basis. (21, 22) 
“Pharmaceutical care reflects a systematic approach that makes sure that the patient 
gets the right medicines, in the right dose, at the right time and for the right 
reasons.”(1) 
Care plans enable the identification of a patient‟ pharmaceutical needs and allow 
these needs to be organised in a systematic manner to achieve goals of therapy. It is 
also a way of documenting the pharmacists work. A care plan is supposed to help 
see and resolve drug therapy problems and prevent new ones from developing. “The 
key to a successful care plan is clear, measureable goals of therapy which include a 
parameter, desired value(s), and a timeframe for achieve them.”(21) The care plan 
should include the care issues together with the desired output(s) and the action 
planned to achieve the output(s).(21, 23)  
Having hospital pharmacists doing „clinical work‟ has shown to identify and reduce 
important drug related problems, improve patient education and compliance, improve 
prescribing, „clinical outcomes‟ and cost effectiveness, and to reduce rates of 
readmission and length of hospital stay. The presence of the clinical pharmacist on 
the ward is now generally welcomed as a source of information and advice by 
medical, nursing and other ward staff in Scotland; they are a part of a 
multidisciplinary health care team. The „Framework for Practice‟(24), published in 
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1996, recognises the need for pharmacists to participate fully as members of the 
team, and pharmacists in Scotland are now actively supporting drug and therapeutics 
committees, ward rounds, therapy review rounds, nurses‟ meetings, discharge 
planning meetings, case conferences, clinical meetings and unit meetings. (24) But the 
concept of pharmaceutical care has still much to offer, and there should always be 
room for improvements. It is recommended that the pharmacists should design 
protocols (local treatment guidelines), document problem solving and increase the 
level of teamwork and continuity of care to help improve the system they are working 
within. To achieve this they should improve their own personal level of practice by 
improving their knowledge as well as communications skills and attitudes to patients 
and teamwork.   
1.2.1 Pharmaceutical care in mental health  
The role of a hospital pharmacist has since the 1960‟s changed from being a 
dispensary based supply and support role to a primary ward/team based role. The 
mental health trusts (MHTs) have however suffered from a number of mistaken 
assumptions on how they don‟t need to develop their own specialist pharmacy 
service. It has been thought that the generic acute trusts would provide this expertise 
and that developments from acute trusts can be directly transferable to MHTs. MHTs 
however support people over a longer period of time and covers a larger 
geographical area with small units. The magnitude of medicines management may 
also differ since medication within mental health is more emotive and complex, with 
risks including inappropriate dosing, poly-prescribing and inadequate patient 
monitoring. In order to reverse these assumptions, “The new ways of working for 
pharmacists and other pharmacy staff programme” (25), were developed in 2001. This 
programme has amongst many other things shown that the presence of a pharmacist 
in the clinical/ward/community team is likely to improve relationships, improve 
medicines management and lead to better outcomes for service users. It has been a 
vital part of the transition from pharmacy being a neglected area to highlighting the 
need for it to be a key clinical service.(25-27)  
Mental health is now one of the Scottish Executive‟s health priority areas alongside 
cancer and heart disease (28). In 2002 the Scottish Executive (now referred to as the 
Scottish Government) published “The Right Medicine: A Strategy for Pharmaceutical 
Care in Scotland” (1). Some priority areas were discussed and mental health was one 
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of them. The document highlighted the contribution pharmacists can give to the 
management of psychiatric and other medicines, and how they can help promote 
patient compliance. To ensure that high quality pharmaceutical care was provided 
across Scotland, the document endorsed development of “an integrated pharmacy 
record and decision-support system"(1).  
Last year the Health Care Commission published a report “Talking about medicines; 
the management of medicines in trusts providing mental health services” (26), were a 
review of medicines management in 42 trusts (out of 83), that provided specialist 
mental health services in England and Wales, were carried out. It was released at the 
same time as “The best medicine: the management of medicines in acute and 
specialist trusts.”(29) The same methodology was used in both the mental health and 
acute trust reports, and results were compared. This comparison shows that the level 
of medicines management support were less within mental health than those found in 
acute trusts. It also shows that about 67% of suggestions made by pharmacy staff 
was acted on in mental health trusts and that pharmaceutical interventions reduce 
harm for one in every 29 patients (compared to one in every 26 in acute trusts). 
Medical reviews showed that 46% of the patients did not take their medicines 
appropriately (compared to 12% in acute trusts) “Talking about medicines...” includes 
a checklist of recommendations to the MHTs on how to improve medicines 
management and how trusts should aim to deliver the same standards of care. This 
checklist is displayed in table 1 below. The Health Care Commission recommends 
that trusts review their strategy and leadership in relation to medicines management 
according to this checklist, and implement action plans to improve their 
performance.(26, 29) 
The definition on medicines management in the UK Audit Commissions report from 
2001, “A spoonful of sugar” follows; “Medicines management in hospitals 
encompasses the entire way that medicines are selected, produced, delivered, 
prescribed, administered and reviewed to optimise the contribution that medicines 
make to produce informed and desired outcomes of patient care“(30)  
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Table 1: Ten focus areas for medicines management within mental health 
Ten focus areas for medicines management 
1. Involving people in decisions and management of their medicines 
2. Ensuring appropriate and effective use of medicines in people‟s care 
3. Efficiently and effectively providing and administering medicines 
4. Promoting multi-disciplinary team working to provide seamless care 
5. Coordinating care with other service providers 
6. Governing use of medicines 
7. Choosing and prescribing medicines 
8. Ensuring staff are competent to work with medicines 
9. Accurately recording and reporting on use of medicines 
10. Supplying and managing medicines in the trust 
 
Mental health services are also a key theme in the NHS Quality Improvement 
Scotland (NHS QIS) work programme, and different approaches towards 
improvements have been taken over the years. In order to improve service 
effectiveness and quality, and to be able to routinely measure outcomes of this, they 
want to implement Integrated Care Pathways (ICPs) to the mental health trusts, 
based on shared planning and meeting individuals needs. “An ICP is a 
multidisciplinary outline of anticipated care, placed in an appropriate timeframe, to 
help a patient with a specific condition or set of symptoms move progressively 
through a clinical experience to positive outcomes” (31). Their use as a tool in 
healthcare is well developed and has shown to have many benefits. An ICP can 
reduce duplication of work, improve communication, and clarify who does what, 
where and when. Individual wards in some trusts have started to introduce ICP, but 
many still have a long way to go. (28, 31) While waiting for, or as a way towards, the 
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implementation of ICPs, Scotland can benefit from a national standard in ways of 
working for pharmacists.  
1.2.2. The development of standardised pharmaceutical care plans 
Since 2002, work on a national system of care plans has begun in priority areas (4). In 
2003, Macintyre et. al. developed and tested a documentation system (care plan) for 
cancer patients receiving chemotherapy (27). They concluded that the development of 
the pharmaceutical care plan has standardised the provision of pharmaceutical care 
to patient receiving chemotherapy for cancer in Scotland. Krska et. al. analysed a 
study in which pharmaceutical care were delivered to elderly patients on multiple 
therapy in 2001(32). This showed that pharmaceutical care planning encouraged 
interaction with both patients and the multi-disciplinary team.  
The Mental Health Pharmacy Strategy Group (MHPSG) is a national interest group 
which aims to improve the mental wellbeing of the population by providing strategic 
direction to NHS Scotland for the planning and development of pharmaceutical care 
in mental health.  
The MHPSG designed and developed, over a two year period, a generic care plan 
document which they envisaged could be used at a national level to facilitate 
pharmaceutical care planning (4). The generic pharmaceutical care plan comprised 
two sections: the Longitudinal information sheet, which was one page, intended to be 
completed once for each patient, and the Cross-sectional admission, which was six 
pages intended to be completed on each admission. The plan is laid out in appendix 
1a and 1b. The necessity to develop and introduce such a care plan Scotland-wide 
was encouraged by a series of national reports; Scottish Executive 2006 (33), 2002 (1), 
1999 (34) and 1997 (35).  
In late 2006, NHS Greater Glasgow & Clyde Research & Development Directorate 
funded a project which allowed the newly developed care plan document to be field 
tested within the mental health pharmacy service during a two month period. Sixty 
three pharmacists from all eleven Health Boards and The State Hospital, Carstairs, 
were recruited. The care plan was used on 241 adults, 70 elderly and 16 forensic 
mental health patients from Scotland, in total 327 patients. 
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The aim of the project was to understand how a standardised generic pharmaceutical 
care plan could facilitate the practice of pharmaceutical care planning in mental 
health across Scotland. The research questions can be seen in appendix 2. To 
address the research questions, the participants completed a questionnaire and 
diary. The completed sections on the generic care plan were counted, and existing 
care plans in current use (11 in total ranging from 2 to 38 pages in length) were 
compared.  
Results from this study were positive but several issues in relation to the layout and 
content were identified which had to be addressed before it could be implemented as 
a standardised national document. Comments on the generic plan can be divided in 
three major groups: 
1. Content 
The sections dealing with current medication and care issues were found to be 
difficult to use and labour intensive. Other criticism concerned the lack of 
space for recording relevant information on the patient, and that the sequence 
of sections needed to be changed for the document to flow better. 
2. Layout and length  
Dividing the plan into two separate parts was not well received, and 
complaints were made about too much paperwork and duplications. 
Complaints on duplications were mainly centred around the frequent need to 
enter patient details and between the generic care plan and information held 
elsewhere. At seven pages the document was found to be too lengthy.   
     3. Risk assessment and multi-disciplinary working; 
There was a desire for the care plan document to be adaptable to suit local 
and national developments within the service, most notably the introduction of 
Integrated Care Pathways (ICPs) and risk assessments. 
The report unmasks the different ways pharmacists practice clinical pharmacy in 
Scotland. This project therefore aims to re-develop a standardised care plan 
document that can be used as a national tool for mental health pharmacists. (4) 
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1.3 Pharmaceutical care issues within mental health 
There are a lot of potential care issues regarding mentally ill patients; this section will 
highlight some of the most important issues to be aware of. 
1.3.1 Co-morbidity 
Co-morbidity is when two or more psychiatric or physical illnesses are present in the 
same individual. Psychiatry and physical co-morbidity is common amongst people 
with a mental illness. (2) 
Dickey et. al. conducted a study in 2002 where they examined whether certain 
medical disorders are more prevalent among adults with severe mental illness, and 
whether a co-morbid substance use disorder increases prevalence beyond the effect 
of severe mental illness alone(36). The study showed that adults with mental illness 
have a higher risk of medical disorders than those without mental illness, and that 
those with a co-morbid substance use disorder had the highest risk for five of the 
disorders considered in the study. 
There are several factors that increase the risk of medical disorders that are known to 
be directly associated with mental illness. These are amongst other(36):  
 use of medication with side effects such as weight gain, which are associated 
with diabetes and hypertension;  
 high rates of smoking, which contributes to asthma, acute respiratory disease, 
heart disease and lung cancer;  
 poor attention to personal hygiene, which is associated with skin infections;  
 reduced physical activity and fitness, which contributes to hypertension and 
heart disease.  
 Some medications used are also known to give adverse gastrointestinal 
effects.  
Mental illness and substance use have a poor influence upon each other, and co-
morbidity between these is unfortunately very common. It reflects both a high risk for 
drug use in subjects with mental illness and a high frequency of psychopathology 
triggered by drug use. People with concurrent disorders often fall through the cracks 
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in the health care system, as mental health services may refuse treatment to a 
person with an active drug or alcohol addiction, while addiction professionals may 
believe that a person cannot recover from problem substance use until the mental 
disorder is treated. (36) 
1.3.2. Patient Monitoring 
Individuals with a chronic mental illness are more likely to suffer from poor physical 
health, also since some of the medication used can contribute to physical health 
complications. To maintain the best care for the patient, monitoring of physical health 
and the drugs given are necessary. 
1.3.2.1. Clinical Monitoring 
Clinical monitoring is the term used for monitoring the physical health of the patient. 
Before starting a patient on antipsychotics, baseline tests are required and taken 
throughout the duration of treatment. (14) Tests undertaken are;  
 urea and electrolytes, especially amisulpiride and sulpiride since they are 
excreted renally; 
 full blood count, were clozapine need continuous checks because of the risk 
for agranulocytosis;  
 blood lipids, weight and plasma glucose, which is associated with 
dyslipidaemia, cardiovascular diseases and diabetes type 2;  
 ECG which among other is mandatory for haloperidol; blood pressure, 
because of the association with postural hypotension with clozapine, 
chlorpromazine and quetiapine;  
 prolactin, as some drugs can cause hyperprolactinaemia;  
 liver function tests, especially clozapine and chlorpromazine as they are 
associated with hepatic failure; and  
 creatinine phosphokinase because of the risk for neuroleptic malignant 
syndrome.  
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Before prescribing lithium, cardiac (ECG), renal (serum creatinine and U&Es) and 
thyroid function (TFT) should be checked. U&Es and TFTs should be checked every 
6 months. Since lithium has a narrow therapeutic window and is excreted renally, 
renal failure can cause serious toxic effects. (14) 
1.3.2.2. Therapeutic Drug Monitoring (TDM) 
TDM is the technical term for measuring the concentration of drug in the blood 
(plasma) to ensure that appropriate/therapeutic levels of drug are achieved/ 
maintained. A certain amount of a drug must always be present in the body to be 
effective. The range of drug concentrations that will safely achieve this result is 
known as the "therapeutic window." If the drug concentration falls below this range it 
will not have any effect, and if the drug level rises above the recommended 
therapeutic window, toxic side effects might result. Lithium is a drug with a narrow 
therapeutic window (0.6-1.0 mmol/l) and therefore need to be closely monitored. (14) 
TDM is mostly used to check if therapeutic plasma levels have been achieved, but it 
can also be useful to detect non-compliance or predict or confirm toxicity.  
1.3.2.3. Monitoring High Dose antipsychotic prescribing 
According to the British council report “Consensus statement on high-dose 
antipsychotic medication” (37) from 2006, are up to a quarter of psychiatric in-patients 
prescribed a high dose of antipsychotic medication even though there is no firm 
evidence that high doses are any more effective than standard doses (14, 37). 
 
The Consensus Working Group agreed to take the following as a definition of high 
dose: “A total daily dose of a single antipsychotic which exceeds the upper limit 
stated in the summary of product characteristics or BNF and a total daily dose of two 
or more antipsychotics which exceeds the summary of product characteristics or BNF 
maximum using the percentage method.” (38) The percentage method is carried out 
by converting the dose of each drug into a percentage of the BNF maximum dose for 
that drug and adding these together (where a cumulative dose of more than 100% is 
a „high dose‟).(37) 
 
Antipsychotics in general have a wide margin of safety. However, there is a 
suspected association between high-dose prescription and sudden death. High 
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doses of antipsychotics can affect the cardiac muscle conduction, causing elongation 
of the QTc interval, which can predispose to cardiac arrythmia and is therefore 
associated with an increased risk of sudden death. High doses may also cause 
central nervous system depression, respiratory depression, hypoxemia and seizures. 
Dose-related side effects e.g. parkinsonism, dystonia and akathisia are more 
problematic at high doses, and there is an increased risk of tardive dyskinesia. The 
prescriber, along with the pharmacist and nurse, assumes responsibility for any harm 
to the patient. Monitoring of high dose prescribing consist of three monthly blood 
tests, measuring urea and electrolytes, and ECG to exclude abnormalities in cardiac 
function. Target symptoms should be assessed after six weeks and three months and 
if insufficient improvement in these symptoms has occurred, the dose should be 
decreased to the normal range.(14, 37) 
1.3.3. Interactions 
A drug interaction can be defined as an interaction between a drug and another 
substance that prevents the drug from performing as expected. This definition applies 
to interactions of drugs with other drugs (drug-drug interactions), as well as drugs 
with food (drug-food interactions) and other substances. An interaction is a kind of 
action that occurs as two or more objects have an effect upon one another. Drugs 
can interact with each other in two different ways; pharmacokinetic or 
pharmacodynamic. 
1.3.3.1. Pharmacokinetic interactions  
These are where one drug interferes with the absorption, distribution, metabolism or 
elimination of another drug. Drugs that inhibit or induce hepatic cytochrome P450 
isoenzymes are the major reason for these kinds of interactions. The most important 
isoenzymes for mentally illnesses are shown in table 2 (note that its contents are not 
exhaustive).(11, 14, 21)  
The potential for drug interactions is high for the majority of drugs used to treat 
mentally ill patients. Most antipsychotic drugs and SSRIs are metabolized by the 
CYP450 system, which can make co-prescribing difficult.  
Nicotine can increase the clearance of many antipsychotics by as much as 10 - 50%, 
specially clozapine and olanzapine. The majority of mentally ill patients do smoke, 
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and although pharmacists should be advising the benefits of quitting, they should be 
aware of the potential rise in plasma levels. Interactions involving Hypericum are also 
potentially problematic as it is an inducer of CYP3A4. Hypericum, also known as St 
John‟s wort, is an herbal product which can be bought over the counter (OTC) from a 
variety of health food shops and some pharmacies. It is reputed to be effective in the 
treatment of mild depression. Many people regard herbal remedies as “natural” and 
therefore harmless. They are not aware of its potential to cause side effects or 
interactions with other drugs. This makes it important to address OTCs while taking 
drug history for a patient. (14) 
Table 2: Substrates, Inhibitors and Inducers for selected cytochrome P450 isoenzymes 
(14) 





Disulfiram       
Grapefruitjuice 
Omeprazole  















Paroxetine            
TCA‟s                       
Methadone 
Carbamazepine 
(weak)     







Macrolides          






Prednisolone     
St John‟s wort 
 
1.3.3.2. Pharmacodynamic interactions 
These are where the concurrent administration of drugs has the same or opposing 
pharmacologic actions and alteration of the sensitivity or the responsiveness of the 
tissues to one drug by another. Many of these interactions can be predicted from 
knowledge of the pharmacology of each drug. (11, 14, 21) 
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MAOI interactions with food containing tyramine (e.g. cheese, meat, certain wines), 
and with other drugs, are well established. It can lead to monoamine overload and 
hypertensive crisis. Patients on these drugs need to be advised on how to avoid 
tyramine-containing foods and the possibility of drug interactions. (14) 
Valproate is highly protein-bound (up to 94%) so other drugs that are highly protein-
bound may displace valproate from albumin and precipitate toxicity (e.g. aspirin). 
Other, less strongly protein-bound drugs, can be displaced by valproate, leading to 
increased therapeutic effect or toxicity (e.g. warfarin).(14) 
1.3.4. Patient compliance 
Compliance can be defined as the ability and willingness of a patient to adhere to a 
pharmacotherapeutic regimen agreed upon between patient and practitioner (21). 
Noncompliance occurs when a patient is unable or unwilling to take the drug therapy 
as intended. Due to the nature of psychiatric illnesses and their subsequent effect on 
rationale thinking, noncompliance is often a problem amongst people with mental 
health problems; especially those detained under the Mental Health Act legalisation 
(see section 1.3.5.). However, patients should always be offered the opportunity of 
discussing their medication with a specialist involved in their care. It is a fundamental 
right to have access to information regarding treatment given. That allows the patient 
to make an informed decision based on careful evaluation of the benefits and risks 
involved.(11, 21) 
Noncompliance amongst mentally ill patients can be attributed to (11, 12, 21) : 
 The illness; if their thinking is too disorganised, they may not remember to take 
their medicine or to order repeat prescriptions etc. It is also common that they 
stop taking their medication because they have a lack of motivation, their 
concentration is poor or because there has been a long time since a relapse 
and they feel they have managed the illness. 
 Patient specific factors; they may have a lack of insight where they do not 
realise that any experience or feeling they may have are actually symptoms of 
an illness and that treatment is required to relieve the symptoms/illness. They 
may not have enough knowledge, may be afraid to be addicted, get tired of all 
the monitoring tests or they just don‟t trust the doctors or the explained 
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benefits of the treatment. Another issue may be frightens of stigmatising in 
relations to family and friends. 
 Medication specific factors; some side effects can be so unpleasant that they 
just quit without discussing it with the doctor. The medication can have a low 
efficacy, delayed onset of action on symptoms, or they may not like the 
formulation, like e.g. the taste of the drugs. 
 Doctor specific factors; Drugs may be prescribed without regards to patients 
wishes. Explanation on the importance of continually treatment and the danger 
with sudden discontinuation has been left out.   
When a practitioner discovers that a patient is noncompliant, he/she must be certain 
that the patient‟s medication regimen is therapeutically indicated, effective and safe. 
There are many strategies to help people with mental illnesses improve their 
compliance. One can try to improve tolerability/minimise side effects by checking if 
minimum effective dose is used, if an alternative agent is available or if the side 
effects can be treated. One can also try to simplify the dosing regimen; some 
medications are available in long-acting, injectable forms, which eliminate the need to 
take a pill every day. Medication calendars or pillboxes labeled with the days of the 
week can both help patients remember to take their medications and let caregivers 
know whether medication has been taken. Electronic timers on clocks or watches can 
be programmed to beep when people need to take their pills, and pairing medication 
with routine daily events, like meals, can help patients adhere to dosing schedules. 
Stigma can be minimised by raising awareness of mental health problems with the 
public and improving patient and carer information. (12, 13, 21) 
1.3.5. Consent to treatment plans 
Mental health legislation (Mental Health (Care and Treatment) (Scotland) Act 2003) 
applies to people with a „mental disorder‟, a term used to cover mental health 
problems, personality disorders and learning disabilities. It covers issues to when a 
patient can be taken into hospital against his/her will, given treatment against his/her 
will, what the patients‟ rights are, and safeguards to make sure his/hers rights are 
protected.  
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To make sure that prescribing is appropriate for those patients detained under the 
Mental Health Act, it needs to be documented in consent to treatment plans. (39, 40)  
When a patient is detained under the Act there are certain circumstances and 
situations when treatment can be given without their consent, table 3 set out the 
safeguards and requirements for specific treatments. (38)  
Table 3: Requirement of the 2003 Act for consent to treatment(38) 
The Act allows the practitioner appointed as the responsible medical officer (RMO) to 
treat a patient with a mental disorder without consent for two months when the 
patient is detained. If the patient still will not consent after that, the Mental Welfare 





but does not 
resist or object 
Incapable and 
resist or object 
Neurosurgery 
and deep brain 
stimulation 
Needs DMP 
opinion and lay 
opinions from 
MWC 
Cannot be given Needs DMP 
opinion and lay 
opinions from 
MWC. Must then 
be authorised by 
Court of Session 










on form T2 
Cannot be given Needs DMP 
opinion on form 
T3 and can be 




opinion on form 
T3 and can be 







for more than 
2 months and 
medication 
to reduce sex 




on form T2 
DMP opinion 
on form T3 
with statement 
as to why 
treatment 
should be given 
Needs DMP 
opinion on form 
T3 and can be 




opinion on form 
T3 and can be 










Written consent Best interests 
test – RMO 
records reasons 




in spite of 
refusal 
Best interests 
test – RMO 
records reasons 
for treatment in 
writing 
Best interests 
test – RMO 
records reasons 
for treatment in 
writing 
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Commission will appoint an independent specialist, called a designated medical 
practitioner (DMP), to assess the patient and confirm that the treatment is necessary. 
If the patient still does not agree, all prescribed medication must be detailed on a T3 
form. If the patient agrees to take the medication, the medication needs to be 
detailed on a T2 form. The pharmacist has additional responsibility to make sure a 
patient detained under the Act is treated according to the law. (38-40)  
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2. Aim and objectives 
2.1 Aim 
Design and validate a documentation system that can be used for mental health 
pharmaceutical care planning in a Scottish in-patient population.  
2.2 Objectives 
1. Generate a list of candidate care issues/guideline standards relevant to mental 
health pharmaceutical care based upon a review of the relevant literature and 
authorised specialist reports. 
  
2. Identify (a) data fields and (b) common care issues to be included in a care 
plan from recommendations made by a report to the MHPSG.  
 
3. Re-design (a) the care plan document and (b) a set of guidelines of how to use 
the care planning documentation in light of recommendations from the report 
to MHPSG. 
 
4. Field-test the draft documentation by conducting a survey in one or more 
samples of patients. 
 
5. Validate a draft care plan and the guidelines by receiving feedback from 
SPMH members and practising Mental Health clinical pharmacists.  
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3. Subject and settings 
3.1 Subject 
A research group comprising the researcher, Mona Skarsaune, and the project 
supervisors, Ms Gazala Akram and Professor Stephen Hudson was formed. Miss 
Marianne Van de‟Lisle, principal pharmacist at the REH, was also consulted but was 
not a member of the research group. 
 
3.2. Settings 
3.2.1. Field testing 
The document was field tested within NHS Lothian at the Royal Edinburgh Hospital 
(REH) and the State Hospital in Lanarkshire from January 9th to January 25th 2008. 
The REH provides acute psychiatric and mental health services, including treatment 
for learning disabilities and dementia. Its specialist services include centres for the 
treatment of eating disorders, alcohol problems and young people‟s mental health. 
The State Hospital is one of four high secure hospitals in the UK, where assessment, 
treatment and care are provided in conditions of special security for individuals with 
mental disorder who, because of their dangerous, violent or criminal propensities, 
cannot be cared for in any other setting. 
3.2.2. Focus group interview 
A focus group interview was held at a Scottish Mental Health Pharmacy (SPMH) 
clinical meeting on the 21st February 2008, at the Park Hotel in Falkirk, Central 
Scotland. The group consisted of six pharmacists who all worked in different 
hospitals and in various specialities including General Adult, Rehab and the Elderly. 
Five health Board Areas were represented: NHS Greater Glasgow & Clyde; 
Highland; Tayside; Lanarkshire and Forth Valley. 
SPMH is an interest group, providing a rich meetings program and contact group for 
pharmacists working within the psychiatric field in Scotland. The mission statement 
for SPMH is: „to encourage, develop and promote the delivery of quality 
pharmaceutical care within mental health.‟ 
The Development of a Pharmaceutical Care Plan in the Scottish Mental Health Service 
38 
 




4.1 Literature search 
An extensive literature search using PubMed, Medline and Embase was conducted 
to locate literature detailing the current status on documenting pharmaceutical care 
within mental health. The search terms used were; care planning, mental health, 
mental health AND pharmacists, mental health AND pharmaceutical care, mental 
health AND pharmacists and documentation. 
4.2 Generating candidate care issues and data fields 
A list of candidate care issues and data fields were conducted by; 
 Searching in existing online guidelines such as the Scottish Intercollegiate 
Guidelines Network (SIGN) and the National Institute of Clinical Excellence 
(NICE). 
 Consulting The Maudsley Prescribing Guidelines, 9th Edition which is an 
recognised well respected resource for mental health clinicians with respect to 
prescribing 
 The recommendations from the previous project by the Mental Health 
Pharmacy Sub Group (MHPSG) 
 Getting familiar with the clinical practice of pharmacy within mental health. 
This was achieved by visiting different wards, with different clinical pharmacist 
at the Royal Edinburgh Hospital (REH), and at The State Hospital.  
 Looking through projects previously undertaken by other specialities 
 
All data fields from the REH current care plan, previous projects and the MHPSG 
generic care plan was taken under consideration. In addition NICE guidelines and 
The Maudsley prescribing guidelines were consulted.  
The research group, consisting of the researcher and the supervisors Ms Gazala 
Akram and Professor Steve Hudson, had a meeting in the beginning of December 
where additional care issues and data fields were generated and unnecessary or 
inappropriate ones were removed. 
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4.3 Re-design of the prototype care plan 
The researcher re-designed a draft care plan by incorporating the data fields and 
care issues generated by the researcher. The format chosen was drawn on previous 
care plans designed for use at the REH and in other patient groups (41). Guidance on 
how to use the care plan was also designed together with an example care plan. 
A very early draft was discussed at a research meeting in the beginning of December 
where suggestions for improvement were sought after. Another draft was developed 
and peer reviewed in the second week in December. This was achieved by sending 
the revised care plan, with guidance on how to complete it and an example care plan 
document by e-mail to all the supervisors, including Mrs Marianne Van-De-L‟isle. 
Suggestions for improvements to the document were requested before the Christmas 
holiday. Minor adjustments were made, in late December and in the beginning of 
January, to form a prototype care plan. 
 
4.4 Field-testing 
The care plan was field tested for two and a half week by clinical pharmacists at the 
REH and the State Hospital from January 9th to January 25th 2008 
Before the field testing, an e-mail with the prototype care plan, guidance and 
example care plan was sent out to all clinical pharmacists at the Royal Edinburgh 
Hospital, including the Principal pharmacist at the State Hospital. On the morning of 
January 9th the care plan was discussed amongst the pharmacists and the 
researcher at a clinical staff meeting to make sure all the participants understood 
what was required and how to complete the care plan document. The aim of this field 
testing was to see if the care plan could be used in daily clinical work and to gauge its 
utility as a standardised document. The inclusion criterion for the study was all new 
admissions to the wards during the two and a half week study period.  
The pharmacists were asked to contact the researcher if they had a new admission 
so that she may observe and try to complete the care plan herself. Comments on the 
documents were to be sent to the researcher by e-mail. 
After the field testing the researcher had another meeting with the pharmacists to 
feedback their comments and discuss any planned changes.   
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4.5 Validation of the care plan document 
A focus group consisting of mental health clinical pharmacists from different parts of 
the country was considered the optimal means by which to validate the care plan 
document.  
4.5.1 Focus group methodology  
Focus groups are a method of generating qualitative research data, and consist of a 
group of people discussing a common theme or topic. It normally consists of four to 
12 people and lasts for about one or two hours. It is often defined as a group 
interview, but aims to be more like a discussion rather than an interview. Questions 
should be unstructured, unbiased, non-threatening, and simple.  
The idea is that the participants get engaged in a discussion amongst each other 
instead of directing their comments solely to the moderator. The moderator is the 
person who‟s running the focus group by leading the discussion or indulging in some 
„structured eavesdropping‟. (42) 
The moderator should encourage participation from all, keep the discussion on track, 
and basically act as a facilitator. There can be considerable advantages by having a 
second person involved in the running of the group, especially if there is a lack of 
experience with running it. The second person can help by taking notes and observe 
body langue, themes, enthusiasm, mood of discussion etc., and can give feedback 
on the moderator‟s performance. (42, 43) 
4.5.1.1. Advantages and disadvantages with using Focus Group methodology 
There are many advantages to using focus groups. These include; 
 Time effectiveness; as it allow the researcher to get the opinion of a number of 
people at the same time,  
 Relatively inexpensive; by neither needing a lot of time or equipment,  
 Greater flexibility, as it offers a wider opportunity to probe into issues 
 
Other advantages are that focus groups can work well for people who may have 
limited education, modest verbal skills or other specific difficulties. A discussion also 
gives the participants the chance to make comments in their own words, while being 
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stimulated by thoughts and comments from the other persons in the group. By being 
empowered of their role in the group, people often express views they might never 
expressed in other settings. At the same time people often tend to check and correct 
each other, and that gives sort of a natural quality control on the data collection by  
Disadvantages with focus groups are that it can be difficult to get people to 
participate; you don‟t want to pay them to come, because that can lead to bias as the 
paid respondents may try to say what the researcher wants to hear, and you also 
need to find a time that is convenient for all the participants. Some may find the focus 
group situation intimidating or off-putting, and if the moderator don‟t do a good job it 
can lead to having one or two people dominating the group, and the other 
participants may feel under pressure to agree with the dominate view. If a 
disagreement and an irrelevant discussion arise, it can distract the discussion from 
the main focus. Another disadvantage is the limited number of questions covered. It 
is not recommended to have more than ten questions within an hour, preferably less. 
The data collection may also often be difficult to analyse, and you cannot generalise 
the results as the participants are not randomly sampled. (42, 44) 
Most researchers recommend aiming for homogeneity within each group in order to 
capitalise on people's shared experiences. However, it can also be advantageous to 
bring together a diverse group, for example, from a range of professions, to maximise 
exploration of different perspectives within a group setting, but it is then important to 
be aware of how hierarchy within the group may affect the data; a nursing auxiliary, 
for example, is likely to be inhibited by the presence of a consultant from the same 
hospital. (42, 44, 45) 
4.5.2. Validation of care plan document by peer consensus using a focus group 
approach  
Participants for the focus group were to be recruited from members of Scottish 
Pharmacy in Mental Health (SPMH). On November 27th the researcher attend a 
SPMH clinical meeting to inform members about the project, and to encourage their 
participation for the Focus Group discussion. The Focus Group discussion was 
scheduled for the lunch recess at the next clinical meeting on the 21st February 2008. 
The meeting was held at the Park Hotel, Falkirk, Central Scotland.   
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A week before the meeting on February 14th, an e-mail with the care plan and 
guidance text was sent out to all the members of the SPMH, asking for their 
comments via email to the research team, email to the SPMH chairman, or by 
volunteering to take part in the group discussion. Inclusion criteria for participating 
were that the pharmacist should be regularly using care plan documentation.  
The objective for hosting this group was to find views on how the clinical pharmacists, 
as a group, felt about the care plan document. A topic guide (appendix 3) was 
developed to make sure all the themes were covered. The main purpose was to find 
out if this document could be implemented in their day to day practice, and if not, 
what changes could be made to make it easier to use. 
To help with data analysis the discussion was audio recorded with participants‟ 
permission and the tape was subsequently transcribed for analysis. 
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5.1 Literature search 
The literature search did not identify any published material within the field of 
pharmaceutical care planning in mental health thereby confirming the need for such a 
venture. 
 
5.2 Candidate care issues and data fields 
5.2.1. Candidate care issues 
A number of care issues within mental health were identified, Table 4 lists what the 
research group identified as most important to the practice of mental health 
pharmacy. 
 
Table 4: Pharmaceutical care issues 
No                                       Pharmaceutical care issues 
Drug History 
1 Confirm medical and psychiatric history 
2 Confirm history of non-compliance 
3 Confirm history adverse drug reaction or non responsive therapy 
4 Confirm any problems with drug interactions 
Polypharmacy 
5 Simplify dosing regime 
6 Check if patient gets unnecessary treatment 
7 Check therapeutic benefit 
8 Check treatment of avoidable adverse drug reactions 
9 Switching drugs – check the need for wash out period / titrations 
Guidelines 
10 Conformity to guidelines 
Monitoring  
11 Check frequency and results 
12 Check if drugs with a small therapeutic window 




13 Particularly with CYP 450 for antipsychotics  
Adverse drug reactions 
14 Check if minimum effective dose is used 
15 Check if there are alternative agents 
16 Address different ADR‟s for individual patients 
17 Check treatment – use of anticolinergic drug should be reviewed every 3 – 6 months 
High dose antipsychotics 
18 Check if necessary  
19 Monitor urea, electrolytes and ECG – QTc at baseline and thereafter three monthly. 
Mental Health Act (MHA) T2 / T3 
20 Check if appropriate according to law 
21 Check if all treatment is given in accordance with MHA legislation 
Compliance 
22 Confirm ability to self-medicate 
Patient understanding 
23 Patient awareness of indication for antipsychotic drug therapy 
24 Patient awareness of what action to take if missed dose 
25 Patient awareness of adverse drug reactions 
26 Patient awareness of interactions with other drugs (incl. OTC), food, alcohol etc. 
27 Patient awareness importance of compliance 
28 Patient knowledge of signs of intoxication of some drugs (e.g. Lithium) 
 
5.2.2. Patient data fields 
The patient data fields generated by the researcher are listed in table 5 below. Data 
fields the researcher did not want to include, but that more than one of the sources 
found important, is written in italics. A small explanation on why it was not included 
can be found under comments. 
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Table 5: Patient data fields 
No Data fields Comments 
Patient Details 
1 Name  
2 Preferred forename Slightly used anymore  
3 Local ID / CHI number ID number is much more used 
4 Address  
5  Age / Date of birth (DOB)  
6 Gender (male / female)  
7 Height (m)  
8 Weight (kg)  
9  BMI  
10 Social history With alternatives to tick 
11 Family history  
12 Drug use Including all illicit substances 
13 Alcohol consumption  
14 Smoking status With alternatives to tick 
15 Carer With number and address 
16 Named person With number and address 
17  General Practitioner (GP) With number and address 
18 Community Psychiatric nurse   
19 Community Pharmacy With number and address 
Admission details 
20 Date of admission  
21 Source of admission  
22 Pharmacy log date  
23 Consultant  
24 Clinical Pharmacist  
25 Legal status code  
26 Key worker  
27 Hospital  
28 Location / Ward  
29 Working diagnosis Merge together to become only 
„diagnosis‟ 
Merge together to become only 
„diagnosis‟  
30 Confirmed diagnosis 
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31 Presenting compliant  
32 Self medication  
33 Compliant  
History 
34 Relevant medical history  
35 Relevant drug history  
36 Relevant psychiatric history  
37 Adverse event history  ADR‟s, drug sensitivities, interactions 
Current 
38 Current medication incl. OTC  
39 As required medication (PRN)  
40  Depot injections  
41 Stat doses (one offs) Requested to give as separate section 
42 Medicines if T2 or T3  
Monitoring / investigations 
43 High dose antipsychotic 
prescribing  
 
44 Therapeutic drug monitoring  
45 Weight  
46 Blood pressure  
47 Pulse  
48 Renal function U&E‟s 
49 Liver function tests ALT, GGT, Bilirubin 
50  Blood count FBC, WBC, MCV, PLT, Neutro 
52  Plasma glucose  
53 Hb  
54 Blood lipids Cholesterol, triglycerides 
55 Creatinine phosphokinase (CPK)   
56 Thyroid function THS, Free T4 
57 Prolactin  
58 ECG – OTc  
59 EEG  
References:(4, 14, 41) , Lothian‟s current care plan. (Parameter-abbreviations is shown in appendix 4) 
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5.3 Re-design of the prototype care plan 
The researcher re-designed a prototype care plan by incorporating the candidate 
care issues and patient data fields listed in 5.2.1. and 5.2.2. The format for the care 
plan was similar to the one already in use at the Royal Edinburgh Hospital, and the 
care plan recently developed for diabetes patients (41).  The first draft care plan is 
given in appendix 5, were the main themes of the care plan can be divided into six; 
 General demographic data: Which includes patient details such as name, 
address, date of birth, BMI, gender etc.; general comments which can be social 
and family history; addresses of important people involved with the patient, e.g. 
carer/named person and GP, as well as drug sensitivities, smoking status and 
substance misuse. 
 Admission details: This included why, when and where the patient were 
admitted, as well as diagnose, legal status and hospital staff involved. It also 
had a suggestion to record if the patient were on any drugs that needed close 
monitoring. 
 Patient history: A section meant to record any relevant medical, psychiatric and 
drug history including adverse advent history 
 Monitoring: a sheet to record laboratory tests, divided into care episodes where 
the pharmacist could record the date reviewed, as well as the date the test was 
taken. Therapeutic drug monitoring and monitoring of high dose antipsychotic 
prescriptions were placed right above the care issue recording as it also was 
thought to be recorded more specific there. 
 Current medication: divided into regular-, depot- and as required medication. 
Made administration times for pharmacist to tick and an „other‟ if none of the 
times fitted. 
 Care issues: a care issue check list was not included in the first draft. The 
issues were discussed during a research meeting later. However, it was 
decided that all the care issues concerning treatment changes were to be 
recorded separately from the rest of the care issues e.g. educational needs and 
therapeutic plan checks.  
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A meeting with the research group was held on December 3rd to discuss and validate 
the care plan. The pharmaceutical care issues associated with mental health 
problems were categorised into ten main issues; drug history, polypharmacy, 
guidelines, drug therapy problem (DTP) risk, interactions, adverse drug reactions, 
high dose antipsychotic, Mental Health Act (MHA) T2/T3, compliance and patient 
understanding. These main issues were to be standard care issue checks, as a 
prompt to the pharmacists, to make sure they have thought through all main the 
issues that can arise with a mentally unwell inpatient. Appendix 6 shows the issues 
raised by the research group and suggestions followed. The draft care plan was then 
suitably modified to form a prototype care plan (shown in appendix 7).   
To meet all the recommendations from the original MHPSH report, several changes 
were made to the original generic pharmaceutical care plan. Table 6 summarises the 
changes made to the original care plan to form the new prototype care plan.  
Table 6: Changes made to the original generic pharmaceutical care plan 
No CHANGES MADE ACCORDING TO THE MHPSG-REPORT 
Deletions made to the care plan 
1 duplications 
2 changes to patient details 
3 own discharge box 
4 care issue check levels 
5 summary of progress made during admission 
6 investigations 
Additional space to record all relevant information; 
7 contact details 
8 family and social history 
9 weight/height and BMI 
10 drug sensitivities to top of first page 
11 smoking status 
12 substance misuse 
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13 history of non-compliance together with „relevant medical history‟ 
14 relevant drug history (incl. adverse or non responsive therapy) 
15 pharmacists monitoring reviews – (date and sign) 
16 clinical monitoring 
17 monitoring of high dose antipsychotic prescribing 
18 if patient is self medicating or not, 
19 if the patient is under T2 or T3 
20 depot injections separately 
21 as required medication 
22 standard care issue checks 
To increase logicality 
23 changed the layout 
24 made it possible to use patient label 
25 made lager space for some of the data fields 
26 changed the current medication sheet completely (because it was said to be 
messy & difficult to reed, time consuming & cumbersome) 
27 changed the care issue section completely (because no one understood it);  
28  made standard care issue checks and moved them to the top of the 
individualised care issues. 
29  based upon the method previously used and validated in care plan
 
documentation for patients with type 2 diabetes mellitus (41). 
Increase efficiency 
30 compressed the two documents to be only one document 
31 deleted several sections 
32 changed patient details on the top of each page, to just CHI number on every 
second page (as it will be printed in double pages) 
Duplications 
33 combined the Longitudinal information sheet with the Cross-sectional sheet 
34 deleted patient details on top of every page 
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5.4. Field testing 
Field testing of this new version of the care plan was conducted over 16 days at the 
Royal Edinburgh Hospital and the State Hospital. Twelve care plan documents were 
completed by six pharmacists.  
At the pre-meeting before the field testing, the discussion with the clinical 
pharmacists at the Royal Edinburgh Hospital was mainly centered on how to use the 
care issue section. After the test-period, feedback from the participants was received 
by e-mail, and a second meeting was held to summarise the resistance towards the 
care plan and the suggestions for improvements. The feedback in general, together 
with changes made according to suggestions, is shown in table 7 below. 
Table 7: Feedback in general after the field-testing 
General feedback with changes to the care plan 
Not enough space to write in; 
“have to be a very neat writer to get things into spaces provided” 
 Made more space for addresses and care issues 
 Merged social- and family history to be one comment box 
 Added version nr on top of front page 
Results/clinical monitoring should be moved; 
“better after the prescription sheet, and possibly after care issue section for reference” 
 No changes made (see discussion for argument) 
Clinical monitoring are missing some parameters; 
“If we are ticking and dating to say we’ve checked them, then surely we should just record any 
abnormalities that we are following up on?” 
 Changed to clinical monitoring abnormalities 
 Removed all biochemical references, and left ten lines open to fill in relevant information. 
 
Don’t like the individual care issues, or the abbreviations; 
“Dislike some of the abbreviations, particularly DTP risk, and I can’t quite get the hang of splitting the 
care issues” 
 Changed the guidelines 
 Changed drug therapy problems (DTP) risk to co-morbidity. 
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5.6 Validation of care plan document by peer consensus using a focus 
group approach. 
The focus group consisted of six pharmacists who all worked in different hospitals 
and in various specialities including General Adult, Rehab and the Elderly. Five 
health Board Areas were represented: NHS Greater Glasgow & Clyde; Highland; 
Tayside; Lanarkshire and Forth Valley. 
Since time was limited, as the focus group was scheduled during lunch and had to be 
completed in 45 min, it was decided that the discussion should follow a semi 
structured format that would be primarily led by the facilitator. 
Several issues were raised in relation to the layout and content of the care plan 
document and appear to be largely related to issues of: 
a) Layout of the document  
b) Recording of Monitoring Parameters  
c) Medication/prescription writing 
d) Recording of the Care Issues 
 
5.6.1 Comments on the care plan from the focus group 
Some of the pharmacists were more familiar with smaller care planning 
documentation, and found this document too time consuming. The relevance of 
recording patient history was not seen, as that information can be found in the 
medical records. The impression was that if any specific issues about the patient 






” I’m used to a lot simpler versions, they tend to be more one sheet...” 
“I would say that if I had to fill in one of these for all of my patients, it would be 
difficult to fit in all my other ward commitments.” 
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a) Layout of the document 
The majority thought the document was too lengthy but did eventually agree that 
most of the information detailed on the front page was necessary. Some gaps in 





A request for space to record the care manager were made, and it was suggested to 
make room for recording “other people” relevant for the patients care. A suggestion to 
add compliance aid so the pharmacists can know if the patient needs blisters etc. on 
discharge was made as well.  
The history areas were proposed being without lines to have the ability to write in 




b) Recording of Monitoring Parameters 
This section faced a lot of resistance. Participants wanted the therapeutic drug 
monitoring section to be similar to the clinical monitoring section. This would allow 
trends to be seen at a glance and omit the need for a new line for every new test on 
the same drug.  
The area for recording monitoring of high dose prescribing was equally not well 
received. A general feeling was that this issue should be referred to in the care 
issues section and not be separated from it. For example, one participant said they 
would prefer a box to tick if reviewing was necessary. If there are any problems or 
issues with the prescribing they would record it as a care issue, and therefore found 
this process duplication.  
“The admission has no room for changes if the patient is readmitted, maybe you 
could make a box for previous admissions?” 
”…see the lines in it, do they need to be in it? – if you didn’t have lines, you would fit 
more in.” 






There was also some debate as to who should be recording which parameters, and 
practice in this area is variable. Some participants voiced that the monitoring was the 
nurse‟s responsibility, and that the pharmacist job is to just to review if the patient still 
needs to be on a high dose antipsychotic, whereas others thought the pharmacists 
role should be more proactive.  
 
c) Medication /Prescription Section  
The separation of psychotropic medication from the non-psychotropic medication was 
well received. The overall view was that depots should be included in the 
psychotropic medication section. A few of the pharmacists wanted the recording of 
medication start and stop date to be closer or next to each other, with the argument 
that it would make it easier to see if the drug had been discontinued. They also 
wanted some indication of the level of self medication, and suggested that level-





“One thing I would say about high dose is; these monitoring are nurse 
responsibility – it isn’t in our job prescription to make sure they do the TPR’s and 
ECG’s.” 
“...my only care issue is; is it still needed? .....would like a box that says reviewed, 
so that I could see if I’ve asked them” 
 “All problems with this type of prescribing will be recorded under care issues 
anyway” 
“I would document that (high dose prescription) in my care issues and medical 
notes – I don’t see why I would have to replicate it in a section here...” 
 
“Psychotropic is psychotropic – don’t need to separate out the depots.” 
“...in the kardex we use; it’s not separated out anymore.” 
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d) Recording of the Care Issues 
The group was generally positive with the concept of standard checks, but wanted 
more blank spaces in case a care issue did not fit into any of those identified. They 
also suggested that there should be a prompt in the individualised care issues 
section where one could insert the corresponding standard check number, such as 
the date-column. 
The format where the individualised care issues are separated into two columns 
raised a lot of negative comments. Participants generally found this section labour 
intensive and difficult to understand. There was little effort to try and see if it could 
work after appropriate training, and too much emphasis on that this was different 
from what they were used to.  
 
To summarise the comments from the focus group, table 8 shows a synopsis of the 
general statements. 
”…maybe have a few blank checks’ if the care issues you have don’t match the 
standard ones?” 
“...this is a bit more complicated than I am used to.” 
“It is not the way I work!” 
“I’m not sure how I would have split into two columns........I wouldn’t separate it.” 
“I think I would get really frustrated with myself because I’m going to write it in the 
wrong column and then go; Oh no! – and I’m going to rewrite it, and then that’s going to 
annoy me!”   
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Table 8: Synopsis of the general statements from the focus group 
To minimise effort; 
 
Need some adjustments in the layout to make notes fit 
better. 
Take out the lines in all history boxes. 
To be more logical; 
 
Merge some of the boxes, e.g. depot section with 
psychotropic medication 
Change the therapeutic drug monitoring to see trends. 
To include all the 
information necessary; 
Need space for readmission. 
Need level of self medication. 
Visionary statements; To time consuming with the new way of recording 
individualised care issues.  
Duplicates with information held elsewhere (e.g. ICP). 
 
 
5.6.2. Guidance text 
Participants had little to say about the guidance document and seemed happy with its 
content and layout.  
 
5.7 Changes to the care plan after focus group 
All the comments and suggestions from the focus group meeting, together with the 
comments from the field testing, were closely considered when adjustments were 
done to complete the final version of the care plan document. Not all suggestions 
were followed but the rationale for this is mentioned in the discussion. Changes made 
to the document as a result of the focus group comments are listed in table 9.  
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Table 9: Changes to the prototype care plan, according to the focus group comments 
Space 
 The admission line was made bigger to make room for readmission 
 The table division line in the history boxes were deleted 
Monitoring 
 The therapeutic drug monitoring box was made a part of the clinical monitoring 
 table, to that it would be easier to identify trends or patterns in results 
Medical recording 
 tick-boxes for level of self medication included on top of the current medication  
sheet 
 Merged depot section with psychotropic medication 
 Changed the guideline text by adding that one could draw a red line over the  
drug that has been discontinued to see more easily which drugs has been stopped. 
Care issues 
Changed the “date”-column to “date and no” for recording standard checks, guidance text was also 
changed to explain how to use that column. 
 
The finalised version of the care plan is shown below, and the guidance text and 
example care plan can respectively be seen in appendix 8 and 9 
PHARMACEUTICAL CARE PLAN - MENTAL HEALTH  
 







CHI # Gender 
 
Male         
Female     
 
General Comments (e.g. social & family history) 
Age / 



























































Discharge Date Advanced   Y 
Statement   N 





RELEVANT MEDICAL HISTORY (INCLUDING HISTORY OF NON-COMPLIANCE) 
Date  Description Date Description 





RELEVANT DRUG HISTORY (INCLUDING ADVERSE OR NON RESPONSIVE THERAPY)                                                     
Date Medication Comments Date Medication Comments 
      








PHARMACIST’S MONITORING REVIEWS 
Date             
Sign             
CLINICAL MONITORING ABNORMALITY 
Date                 
Weight (kg)            
Blood pressure            
Creatinine          (60–120) µmol/l            
Na                      (135-145)mmol/l            
K                            (3.6-5) mmol/l            
Ca                        (2.1-2.6)mmol/l            
Urea                   (2.5-6.6) mmol/l            
Blood glucose    (3.5-5.8) mmol            
ALT                            (10-50)  µ/l            
GGT                              (5-55) µ/l             
Bilirubin               (3-16)  mmol/l            
WCC                      (4-11)  x 10
9
/ l            
Neutrophils            (2-7.5) x10
9
/ l             
Platelets           (150-350) x 10
9
/ l            
Hb                            (11-18)  g/dl            
Chol esterol       (3.9-7.8) mmol/l            
HDL            
CPK                   (25-170) F    IU/l 
                           (25-195) M   IU/l     
           
TSH (age related)             
ECG            
            
            
            
            
            
            
            








Conc Time & 
date of 
sample 
Conc. Time & 
date of 
sample 
Conc. Time & 
date of 
sample 




            
            
            
            
            
  








BNF % Confirmation of Monitoring 
Initial and date  
Stop date 
 
Baseline 3 Months 6 Months 9 Months 
         
         
         
         
         
         
Patients CHI-number: 
CURRENT MEDICATION 
        
Date: 
SELF MEDICATING               Y     N    
Level                               1   2    3 
Start 
date 
Psychotropic Medication  
incl. depot’s 
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AS REQUIRED MEDICATION 
Start 
date 









         
         
         
         
         
         
         
         
         
 
STANDARD CHECKS IDENTIFYING PROBLEMS WITH; 
1.Drug history    3.Guidelines     5.Interactions  7.HD antipsychotics  9. Compliance                   
2.Polypharmacy 4.Co-morbidity  6.ADR’s          8.MHA T2/T3             10.Patient understanding  
            







Therapeutic Plan Checks + Documentation 
Changes + Patient Education 
Therapeutic Plan Changes 
(Individualisations/ Dosage Change/  Treatment Interruption/ 
Management of Co-morbidity) 
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REGULAR CURRENT MEDICATION 
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This has been a successful project in meeting the aims outlined in the protocol. The 
researcher has managed to produce a documentation system which with further 
validation and minor adjustments may be used to create an agreed future national 
standard within Scottish mental health in-patients. The combination of validation 
methods provided opinions from both practice and theory, and the desirable mixture 
of pharmacist participating in the focus group discussion was achieved. 
The project also managed to meet many of the original MHPSG recommendations, 
such as improvements to the original generic pharmaceutical care plan through 
changes to individual sections, as well as changing the layout and making it more 
compact.  
 
6.1 The need for the project  
The literature search showed that it is a low amount of research done on 
pharmaceutical care in general, and that it is an obvious research area in the future 
for pharmacists worldwide. Documentation is necessary for quality assurance of what 
pharmacists do, including peer review where pharmacists can compare ideas of good 
practise. There was a definite lack of systems for documenting delivery processes 
and outcomes, but work on national systems of care plans has begun in priority areas 
(32, 41, 46). The cancer care plan project by Macintyre et. al. in 2003(46) shows that 
standardisation helped strategic decision making across Scotland. A national system 
within the different specialities will provide standardisation of patient care, as well as 
giving an opportunity to measure outcomes through statistics.  
Improving mental health services in Scotland is a top priority for the Scottish 
Executive(28), and in their delivering plan for Mental Health(33), published in 2006, 
they expected to see arrangements for standardised joint assessments. They 
envisaged that this wide-ranging plan would change the way mental health services 
are delivered in the future, and one of the targets in this plan was to reduce the 
number of hospital re-admissions by 10 percent. As studies has shown that 
pharmacists help reduce rates of readmission and length of hospital stay(24), 
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pharmacists obviously need to be included in this plan. The Scottish Executive also 
highlighted the differences between the mental health services in large cities and 
those in remote and rural areas; they want to see that good standards of care and 
treatment are available regardless of the location(33). Developing a nationally agreed 
care planning system will definitely contribute to that.  
 
6.2 Bringing a research approach into the team delivering the service 
It is thought that the researcher, as a pharmacy student, would be more objective 
developing a national care plan than an experienced pharmacist with acquired ways 
of working. The researcher was not biased by an own care plan, and had to read all 
guidelines and necessary literature to make sure everything was included. Had an 
experienced pharmacist been assigned this project instead, he/she might have 
favoured an own care plan, and maybe trusted him- /herself more in knowing the 
literature and guidelines by heart. The project obviously needed experienced 
pharmacists opinions, but having an „outsider‟ doing the ground work and final 
decisions might have been beneficial.  
 
6.3 Familiarity with mental health clinical pharmacy practice 
To get more familiar with mental health clinical pharmacy practice in Scotland, the 
researcher attended an introduction course in clinical pharmacy at the Strathclyde 
University. This course and the literature search, together with a visit to the State 
Hospital and different wards at the REH, made the researcher understand the need 
for this project. The researcher got a comprehension of the importance of 
documenting pharmaceutical work, and it became apparent that pharmacists have 
different approaches in meeting the patients need.  
The time the researcher spent with mental health pharmacists, at the State Hospital 
and the REH, also gave an opportunity to discuss what they did and did not like 
about the previous care plan in person, as well as how they found their current care 
plans to work in practice.  
The biggest resistance towards the original MHPSG care plan seemed to be the 
‟current medication‟ and the „care issue levels‟. The researcher found the „care issue 
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levels‟ understandable, and thought it made a good prompt, but saw the need of 
changing it based on the large and unanimous resistance towards it.  
The Lothian care plan document had already received favourable comments in the 
previous report(4), and it appeared that the pharmacists at the REH and the State 
Hospital were quite happy with the document they were currently using as well. 
Favouritism of own care plans seems to be a trend throughout all of Scotland. Most 
of the pharmacists are happy with the way they work today, and are not too pleased 
about having to change it. This is a normal behaviour for all human beings: if they 
think they are doing a good job, why change it? Easy to understand, but as time goes 
by everybody should have an aim to improve themselves. There are always new 
research and medicines coming up in this field. Pharmacists cannot be timid in 
embracing change. If they are, they will soon become obsolete and less needed. This 
project is not to say that some do it right and some do it wrong, it is to make a good 
prompt for all the pharmacist to work after so that one can know that the patients gets 
the same quality of pharmaceutical care. 
 
6.4. Design of the Care Plan 
This project was a continuation of the project carried out by the MHPSG in 
2006/2007(4), and can therefore be seen as a re-design of the original generic 
pharmaceutical care plan. This section will discuss the development of the final care 
plan in relation to the changes made to the original MHPSG care plan based on 
comments from the MHPSG report and the mental health pharmacists that 
participated in the validation process. 
6.4.1. Additions 
Duplication of effort was identified as a major problem, and changes were made to 
reflect this. An effective use of time and space could be achieved by using a sticky 
backed printed patient label for patient details, and CHI numbers on top of each page 
instead of full patients‟ details. 
The patient details section was missing important details on physical characteristics 
such as weight, height and BMI. These were found relevant to include due to the risk 
of weight gain as a side effect of medications used to treat mental illnesses. Details 
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of smoking and substance misuse were also included in this section because of the 
interaction between cigarettes and certain medicines, especially the risk of an 
increased plasma concentration if the patient should suddenly quit smoking, and the 
bad influence substance misuse has on mentally ill patients. Substance misuse may 
also affect patient compliance as it can contribute to a feeling of not being ill and 
make it easier to forget to take prescribed medication.  
An area for recording family- and social history were provided in the first draft of the 
document, but that was changed to be an area for general comments during the 
validation process due to lack of use. The segment for recording drug sensitivities 
were moved to the patient details section to increase logicality, and the areas for 
recording community cares, such as the GP, were increased to make room for 
addresses and telephone numbers.  
Several segments in the admission details section, such as presenting compliant and 
diagnosis, were increased to make room for all necessary notes. The legal status 
was increased to provide space to record any changes that may occur during a 
hospital stay, and the segment for the admission date and source was increased to 
make room for readmissions.  
In order to get a good synopsis of the patient history, relevant drug history was added 
in addition to relevant medical and psychiatric history. The area was designed to also 
include ADR‟s and OTCs. Inclusion of OTC would serve as a prompt when taking 
drug history/current medication. Use of OTC medications may often be a relevant 
care issue in mentally ill patients, particularly with regards to the interaction between 
Hypericum (St John‟s Wort) and drugs metabolised through the CYP450 system. The 
medical history was re-designed to include any history of non-compliance that might 
have occurred in the past, so one if necessary can be extra aware in the future. All 
the history segments was made bare so the pharmacists would not feel restrained to 
only use one line to record any relevant history about the patient. 
The monitoring areas in the original care plan were thought to be too small, and to be 
of no use as a prompt on what to record. A whole page was made available for 
recording: monitoring reviews, where the pharmacists only needs to write the date 
and sign if parameters have been reviewed; clinical monitoring abnormalities, where 
trends can be seen for any abnormal tests; monitoring for high dose prescribing, 
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where the pharmacists can insert date and sing when monitoring of the patient has 
been done according to guidelines; and therapeutic drug monitoring. Having an own 
area for recording if high dose prescribing have been monitored makes a good 
prompt in remembering to calculate the doses and making sure the monitoring is 
done according to guidelines.  
Mentally ill patients are often exposed to comorbidities(36), and will therefore need to 
be monitored for other physical irregularities beside the “typical tests”. The clinical 
monitoring table was therefore made out with a few blank lines for recording any 
other tests that may be needed. 
The top of the current medication sheet was arranged so boxes could be ticked if the 
patient is self medicated, and additional boxes were made to tick for the patient‟s 
level of self medication. As the pharmacist has an additional responsibility making 
sure patients detained under the Mental Health Act are treated according to law, 
space was provided to record if medications are listed on a T2 or a T3 form.  
6.4.2. Deletions 
Several deletions were made in order to shorten down number of pages in the 
document. Both the areas for „discharge‟ and the „summary of progress made during 
admission‟ were deleted, and admission date and source were merged. The 
discharge information was mainly well received, except for the lower part on why the 
discharge did not go as planned, but it was believed that this information could 
manage with just a segment for „discharge date‟ under admission details. If any 
pharmacological problems lead to a change in the planned discharge, the 
pharmacists have the opportunity to document that as a care issue under 
„individualised care issues‟. This also applies to progress during admission; problems 
arising during admission should be documented with the outcome under „individual 
care issues‟. The own area for adverse event history in the original MHPSG care plan 
was deleted to be a part of the drug history instead.  
The current medication was one of the most criticised sections of the original care 
plan as the majority found it very difficult to use. The layout of this section was 
changed completely by making it look more resembling to prescription kardex‟s used 
on the wards. In the process of changing it, the medications were divided into 
psychotropic, non-psychotropic, and „as required medication‟. Depots were also 
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separated out in the first draft. The validation process indicated that there was no 
need for such a separation and since this division is no longer a standard in the new 
kardex‟s, it was merged with the psychotropics. This also gave more space for 
recording „ordinary‟ psychotropic‟s if depots are not used. 
The area for investigations was deleted to become clinical monitoring abnormalities 
instead, and the therapeutic drug monitoring (TDM) was changed to be a part of that 
table. This was a desire from the focus group participants as this would enable them 
to view the trends. In order to make the TDM fit, the medications start date and dose 
were deleted as that can be found under current medication anyway. 
Since the care issue level section attracted so much criticism in the previous study, 
the redesign process was significantly concentrated in this area.  A whole page was 
deleted, and instead standard care issue tick box checks were incorporated at the 
top of the individualised care issue sheet. The DTP-risk check, included in the 
prototype care plan, received some inferior comments during the field testing so it 
was replaced with comorbidity. DTP is an abbreviation for drug therapy problems, 
which is more likely to be a joint description of many different care issues, whilst 
comorbidity is a huge problem amongst mentally ill patients that often can lead to 
pharmaceutical care issues. The numbers of the care issues can be recorded with 
the specifications in the individualised care issue section. The standard checks are 
thought to act as a reminder of what problems to assess in each patient. It might also 
be a help to systematise all the care issues, so identification of specific care issues 
will be easier to perform and statistics over checks can be generated.  
The care issue section in the original care plan was laid out somewhat different than 
the pharmacists were used to, and some of the comments in the report was that they 
would prefer to have the pharmaceutical care issue section divided into; care issue ; 
action; output, like they were used to. The new care plan arranged for this in addition 
to division into therapeutic plan changes and other issues, like therapeutic plan 
checks, documentation changes and patient education needs. This was based on a 
care plan developed in 2007 for patients with diabetes(41). The new layout of the 
individualised care issue section was found to be a good way to get a quick synopsis 
of the treatment changes during admission. 
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6.4.3. Changes not incorporated 
Complaints about duplication were also made in relation to the recording of patient 
history. However, it was felt that this section should remain, as not all pharmacists 
have access to ward notes at any one time, and that searching through other notes 
may not be the most efficient use of time. The history sections received complaints 
on scarcity of space during the validation process. Taking the whole document under 
consideration, the areas were not increased. If understandable cues of relevant 
history are used, there should be enough space to write all necessary information. If 
further information is needed this will be available in the medical notes. 
The area for monitoring high dose prescription also faced some resistance during the 
validation process, and was suggested to be removed due to duplication with the 
care issue section and lack of relevance. It is believed that this area makes a good 
clinical prompt so the area was not deleted. It is true that it is not the pharmacists job 
to make sure the nurses do their job, but it is however the pharmacists job to make 
sure the patient gets the right treatment, and that there will be no complications due 
to medication. This includes checking laboratory results for efficacy and safety of the 
medication given. If the monitoring has not been done, the pharmacist cannot confirm 
continuation of treatment. Having an own monitoring area for high dose prescribing 
will cause information to stay united, and make it easier to get a quick overview. 
The monitoring sheet was suggested to be moved after the field testing, but as long 
as the monitoring sheet is facing the prescription sheet, it should not be a problem. 
Some of the participants in the focus group wanted the start and stop dates to be 
next to each other on the current medication section to better see which drugs have 
been discontinued. As this will give the pharmacists a good opportunity to make 
mistakes, it was not incorporated. Instead the guideline was changed to explain that 
if a drug has been discontinued one could draw a red line over it.  
It was also asked for some additional blanks with the „standard care issue checks‟ if a 
care issue should not fit under any of the listed categories. This was not done due to 
lack of space, and the fact that these checks had been considered to be the 
standards. These checks may be used to generate statistics over frequency of 
„standard care issue checks‟. If some health board areas needs to add additional 
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„care issue checks‟ to get the statistics they want, they can feel free to add a number 
for that under „date and no‟ without it being the standard way of recording. 
Splitting the care issues was not well received during the validation process. This is 
obviously a new way of recording, but with proper guidance and training it should not 
be too hard to get used to. All the resistance towards it may be due to unfamiliarity, 
and the fact that the pharmacists included in the validation process were not very 
open to changes. It was found to be a good way to get a quick synopsis of the 
treatment changes during admission, and should be tested out. The only change 
made was in the care plan guideline, to try and explain the application of the section 
in a more easy and understandable way. Other specialities, like diabetes, have also 
made this a part of their standardised care plan(41), why would it be so much more 
difficult for mental health pharmacists to use it? Maybe this is the future?  
Some of the pharmacists were not used to very comprehensive care plans, and 
found this document too time consuming. But as all the literature and the MHPSG- 
report have been consulted, this amount of information was found necessary. If 
important information about the patient and his/hers care are recorded in sections, it 
would make it easier to get a synopsis of the most important issues. If the new care 
plan is compared with the original one,  one can see that the new care plan has been 
merged to be only one booklet, and the number of pages has been decreased from 
seven to four (six if the extra page is added). The new care plan would therefore 
comprise all the necessary information in a much smaller and understandable 
document. 
 
6.5 Pharmacists’ contributions and reactions 
Piloting the care plan at the REH and the State Hospital was well received by the 
clinical pharmacists working there. They were happy to try use to the care plan, 
although they were satisfied with the one they were using now, and understood the 
purpose of having a standardised care planning system.  
However, findings from the focus group discussion suggest that the pharmacists 
were not very interested in using a new standardised care plan document. It 
appeared that there was a certain resistance and lack of interest towards the project. 
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They just kept comparing the new care plan with their own, as it seemed they thought 
that was the best way of recording pharmaceutical care. They did not see the 
intention of creating a new care plan as it is suppose to be a part of the ICP soon. 
Implementation of ICPs has been a plan for many years, but no one actually knows 
when it is going to happen. However, one of the commitments in the Scottish 
Executive‟s mental health delivery plan was that the NHS QIS would develop the 
standards for ICPs for schizophrenia, bi-polar disorder, depression, dementia and 
personality disorder by the end of 2007, and that NHS Board areas would develop 
and implement ICPs that would be accredited from 2008 onwards(33). The 
development of a nationally agreed template pharmaceutical care plan for use within 
mental health settings may be useful in the implementation of the ICPs. 
Another interesting aspect was to see the differences in what the pharmacists found 
important to document. It seemed as one of the pharmacists could have managed 
with just the patients name and his/hers care issues, where others needed more 
information included. One did not want the monitoring- and history boxes, but needed 
an own box to tick what kind of self medicated level the patient is on. Looking at all 
the comments together, shows that tick boxes for level of self medication is thought 
to be more important to include in a standardised care plan than e.g. a synopsis of 
monitoring high dose antipsychotic prescribing. What is more important for the 
patient‟s well being? There is a suspected association between high-dose 
prescription and sudden death(14), whilst non-compliance can cause deterioration of 
the illness. The pharmacist obviously needs to make sure that the patient is able and 
willing to take the medication prescribed, but one will think that making sure that 
patients on high dose antipsychotics are being properly monitored should be just as 
important.  
The pharmacists need to be able to see the importance of documenting the work they 
do. They should have an aim to try getting everybody to work more similarly and then 
eventually create a consistent standard of care. If pharmacists do not document what 
they are doing, they will have no proof that they have done their job if e.g. something 
goes wrong. One can see their point of having access to medical notes when it 
comes to patient history, but it is not the intention to copy all the information on to the 
care plan, just the history relevant to make sure the patient gets the right treatment. It 
The Development of a Pharmaceutical Care Plan in the Scottish Mental Health Service 
74 
 
will make the job easier if they do not have to read through many pages of history 
every time they need some information. 
Complaints on the amount of effort needed to complete the care plan seemed to be a 
return in all validation processes, which make one wonder if maybe the pharmacists 
have too many obligations. This new document is thought to include what is 
necessary to record for satisfactory care of a patient, if they do not have time for that 
a review of the workload should be conducted. 
 
6.6. Design methods and their limitations 
6.6.1. Field testing 
The major limitation of the field testing was the short study period of just two and a 
half weeks, and the small number of care plans completed. This was mainly due to 
staff holidays and the lack of new admissions.  The State Hospital returned even 
fewer completed care plans, but that was expected because of the nature of its 
admission/assessment periods. The care plan was only used within the REH and the 
State Hospital, and cannot be representative for all of Scotland, nor can it show the 
usefulness on long term hospital stays.  
The clinical meeting before the field testing started was to make sure everybody 
understood all the sections in the care plan so they would be able to use it as 
intended. The discussion also dealt with the need for the pharmacists to be critical to 
the care plan during the evaluation, as their apprehension of being rude became an 
issue. They were asked to write down all the difficulties as they were encountered 
during the field testing. To get a practical feel for the care plan, the researcher asked 
to accompany the clinical pharmacists when a new patient was admitted, and it was 
agreed that they would notify the researcher if they could fit it into their time schedule. 
Since the researcher only got contacted by one clinical pharmacist, one can assume 
it was two very busy weeks, or that they just did not find it necessary to include the 
researcher.  
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6.6.2. Focus group 
The researcher chose to host a focus group as a method to validate the care plan. 
An interaction between pharmacists from different parts of the country was 
considered to give a worthwhile discussion of the usefulness of the care plan as a 
standardised document within the mental health pharmacy departments in Scotland. 
The time limit on the project, and lack of founding also gave a good reason for 
choosing this time-effective and inexpensive method. Getting pharmacists to register 
for the focus group in advance became an issue, but a final request received six 
pharmacists from different health broads to agreeing to participate.  
The findings from the focus group are restricted to the thoughts and views of six 
pharmacists. They therefore need to be viewed with a degree of caution. It is possible 
that if another cohort of pharmacists had been interviewed, completely different data 
could have been generated. However, the pharmacists were typical of those working 
in Mental Health pharmacy and so could be considered a fair representation of the 
workforce.  
From the outset, it was difficult trying to make the pharmacists understand or 
appreciate the purpose of the care plan. They appeared to lack insight into its 
purpose as a standardised document. They were, as mentioned earlier, largely 
absorbed about their own care plans, and kept comparing the new one with their 
own. Since the group consisted of pharmacists from different parts of the country, 
none of them worked with similar care plans, and everybody had different ways of 
documenting their work. They made little room for changes in the way they work 
today, which made it difficult to talk about the new care plan. But as they were asked 
to try and see beyond their own care plans, the discussion went a little better.   
The lack of preparation by the participants may have also hindered the discussion. It 
appeared that few if any had looked at the document before the meeting, so they 
may have been limited with their views. Some of the volunteers might not have 
wanted to take part but felt unable to decline when asked directly. This could have 
made some effect on the dynamics and flow of the group discussion. If the 
participants had volunteered in advance, and done proper preparations, the 
researcher would have known that they were sincerely interested in the project, and 
that most of their comments would have been carefully thought through. Another 
The Development of a Pharmaceutical Care Plan in the Scottish Mental Health Service 
76 
 
reason the discussion did not flow as well as desired can be attributed to the way it 
was lead. Neither the researcher nor the co-assistant had any experience with being 
a moderator/facilitator; the co-assistant had however attended several focus group 
discussions in the past. 
Reason for not having more than one volunteer in advance could maybe be caused 
by the researcher‟s way of inviting the pharmacists, although the purpose of the 
project was described two months ahead, and an information e-mail was sent out to 
the pharmacist participant weeks before the focus group took place. 
 
6.7 Further recommendations 
This project shows that the development of a national care plan document is a labour 
intensive process. The previous project piloted a care plan for two months, which 
gave an insight in what the majority of pharmacists wanted such a document to 
include. These comments were taken on in this project, but the pharmacists 
consulted during the process do still not fully agree with the usefulness of all sections 
included.  
Since the methodology in this project was somewhat limited, it is recommended to 
challenge the collected opinions with further validation. The care plan should not be 
dismissed based on opinions from one single focus group. Conducting a few more 
carefully planned focus groups, hosted by an experienced facilitator, may be 
beneficial. If proper preparation from both the researcher and the participants in a 
focus group are executed, a dynamic group discussion is more likely to happen.  
Getting pharmacists to use their time on profoundly preparing, and participating in a 
focus group, can be difficult. A solution may be to host the focus group at a place 
easy to access for all participants, and by and with some incentive. Issues 
concerning bias if the participants get paid may be solved by enticing with a fancy 
meal instead. Pharmacists from all eleven health boards should be represented at 
some time in the different focus group discussions.  
The care plan may also benefit from a new national field test over a longer period of 
time. That will need time and funding. Another way could be to implement the care 
plan as a national standard, after new focus groups and adjustments have been 
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made, and then have a review after maybe a half a year, to see if it has improved the 
care planning and that the pharmacists have been able to use it as intended.   
Before any implementation can be done, the pharmacists will be likely to need 
convincing that more pages than present in their existing care plans are worthwhile. 
Workshops to allow all pharmacists to discuss how to use the care plan are likely to 
encourage a more favourable response, especially with a view to the new way of 
recording care issues. Future work will also benefit from implementation of the care 
plan to the Schools of Pharmacy as a part of the training of clinical pharmacists. It is 
important that the students learn how to document, and if they all get the same 
training independent of which school they attend, that will help standardisation of 
pharmaceutical care. 
The optimal way of using a standardised care planning system would probably still be 
the use of a database instead of a paper document, which also would help avoid 
duplication. 
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Implementation of a standardised care planning system is a labour intensive process. 
This project has managed to produce a care plan document which with further 
validation and minor adjustments can be used as a standard document within the 
mental health area. It may be used as a prompt to ensure that all the relevant mental 
health issues are effectively captured, and may also be used as a training toolkit for 
staff new to Mental Health.  
Findings from the validation process show that the pharmacists are not completely 
ready to take on this document as a standard, but it simultaneously shows that they 
need more convincing to take on any document as a standard. They need to 
understand how mental health patients in Scotland can benefit from a standardised 
care planning system.  
It will obviously take some time for the pharmacist to adjust to a standardised way of 
working. Mandatory use of the new care plan document will therefore not be imposed 
on currently practising pharmacists, but it will be expected that they address all the 
issues contained in the standardised care plan document in their day to day practice.  
The Mental Health Pharmacy Strategy Group, as a cohesive national group, should 
provide the means to achieve their aims of having a standardised care plan by using 
their ability to influence the health boards.  
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Draft V4 4/10/5 1 
Generic Pharmaceutical Care Plan 
Longitudinal information 
Patient Details 
Surname             Local ID               
Forename                  CHI number          
Preferred forename        Date of Birth            
Sex Male  Female  
 
Changes to patient details Score out, with a single line, any details which have changed and document 
new information in table below 
Information type New details Information type New details 
    
    
 
Relevant medical history 























Adverse event history (Known Sensitivities, Allergies, ADRs) 
   
   
   
   
   
 
Scotland 
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MHPSG original generic pharmaceutical care plan 
 
Cross sectional sheet 
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Draft V5 4/10/5 




Surname Local ID 
Forename CHI number 
Preferred forename Carer 
Sex  Male  Female Named person 
Date of Birth GP 
Does the person have an advanced statement 
  Yes  No Unknown 







Date of admission Consultant 
Source of admission Hospital 
Pharmacy log date Ward 
Legal status Named nurse/keyworker 





Working diagnosis Confirmed diagnosis 
 
Discharge Information  
Discharge date – planned Discharge date – actual 



















Draft V5 4/10/5 
 
Care Issues 
Tick box if care issue has been considered, circle ticked box, if a problem has been identified ie    
 
Care Issues – level 1 – Treatment/dosage appropriate with respect to the following  
Date         
1 Diagnosis         
2 Physical state complications         
3 Adverse event history         
 
Care Issues – level 2 Monitoring 
 Date         
4 Counselling/education         
5 Therapeutic drug monitoring         
6 Drug interaction         
7 MHA treatment plan         
8 Discharge planning         
9 Polytherapy         
10 High dose antipsychotic         
11 Side effect(s)         
12 Rationale for treatment change         
13 Concordance         
14 Renal function         
15 LFTs/Bilirubin         
16 FBC         
17 ECG – QTc         
18 Hyponatraemia         
         
         
         
         
         
         
         
         
 













       
       
       
       
       
       
       
       
       
 
Draft V5 4/10/5 
Current medication including OTC 
 
Surname Local ID 
Forename DOB 
 
   Comments – including 
any guidelines or 
protocols in use 
     
Medication  Route 
 Date 
      




      
Medication  Route 
 Date 
      




      
Medication  Route 
 Date 
      




      
Medication  Route 
 Date 
      




      
Medication  Route 
 Date 
      




      
Medication  Route 
 Date 
      




      
Medication  Route 
 Date 
      




      
Medication  Route 
 Date 
      




      
Medication  Route 
 Date 
      




      
Medication  Route 
 Date 
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   Comments – including 
any guidelines or 
protocols in use 
     
Medication  Route 
 Date 
      




      
Medication  Route 
 Date 
      




      
Medication  Route 
 Date 
      




      
Medication  Route 
 Date 
      




      
Medication  Route 
 Date 
      




      
Medication  Route 
 Date 
      




      
Medication  Route 
 Date 
      




      
 
Therapeutic drug monitoring 





       
       
       
       
 
Investigations (record what the investigation was and the abnormal result) 
Investigation Date Result Date Result Date Result 
       
       
       
       
       
       
Draft V5 4/10/5 
Care Issues 
 
Surname Local ID 
Forename DOB 
 
All Care Issue (levels 1, 2 and 3) problems should be recorded here.  
 Pharmaceutical Care Issue  Desired Outcome Outcome achieved  
Date Action to be taken/Recommendation/Progress Request Action by 
 Medical  
 Nursing  
 Pharmacy 
 Clinical Team 
 Pharmaceutical Care Issue  Desired Outcome Outcome achieved  
Date Action to be taken/Recommendation/Progress Request Action by 
 Medical  
 Nursing  
 Pharmacy 
 Clinical Team 
 Pharmaceutical Care Issue  Desired Outcome Outcome achieved  
Date Action to be taken/Recommendation/Progress Request Action by 
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 Pharmaceutical Care Issue  Desired Outcome Outcome achieved  
Date Action to be taken/Recommendation/Progress Request Action by 
 Medical  
 Nursing  
 Pharmacy 
 Clinical Team 
 Pharmaceutical Care Issue Desired Outcome Outcome achieved  
Date Action to be taken/Recommendation/Progress Request Action by 
 Medical  
 Nursing  
 Pharmacy 
 Clinical Team 
 Pharmaceutical Care Issue Desired Outcome Outcome achieved  
Date Action to be taken/Recommendation/Progress Request Action by 
 Medical  
 Nursing  
 Pharmacy 
 Clinical Team 
 Pharmaceutical Care Issue Desired Outcome Outcome achieved  
Date Action to be taken/Recommendation/Progress Request Action by 
 Medical  
 Nursing  
 Pharmacy 
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 Pharmaceutical Care Issue Desired Outcome Outcome achieved  
Date Action to be taken/Recommendation/Progress Request Action by 
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 Nursing  
 Pharmacy 
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Research questions from the MHPSG project 
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Research questions from the MHPSG project; 
 
1. How completes the care plan? 
2. When is the care plan completed, e.g. before, during or after MDT meetings? 
3. Is it easy to use the documents? 
4. Are the correct data being collected? 
5. Does the document alter the way of working? 
6. How useful do questionnaire respondents see that the Generic Care Plan is to 
other disciplines within the MDT? 
7. How do the documents help in communicating information to Community 
Pharmacists/GPs? 
8. What are the barriers to implementation of the document? 
9. Is the pre-implementation training adequate? 
10. What data are being collected by the Care Plan? 
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Focus Group Topic Guide 
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Focus Group Topic Guide 
 
How useful do you think this document will be? 
 
Then talk them through the Sections; 
 Personal info 
 
 History sections 
 
 Monitoring sheet 
 




 Individualised care issues 
 
 Possibility of adding an extra sheet 
 
 The order of the pages 
 
 
 Resistance/ Barriers to its use 
 
 Adjustments or changes they think it could benefit from 
 
 Suggestions for improvements 
 
 
Also need to discuss the guidance document and if it’s any help.  
What are the problems with it? 
 
How can it be improved? 
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Parameter abbreviations  
ALT  Alanine aminotransferase 
Bili   Bilirubin 
Ca  Calsium 
Chol.  Cholesterol 
Creat.  Creatinine 
CPK  Creatinine Phosphokinase 
ECG  Electrocardiogram 
EEG  Electroencephalogram 
FBG  Fasting blood glucose 
Free T4 active form of thyroxin 
GGT  Gamma glutamyl transferase 
Hb  Hemoglobin 
HDL  High-density lipoprotein 
K  Potassium 
LDL  Low-density lipoprotein 
MCV  Mean corpuscular volume   
Na  Sodium 
Neutro Neutrophils  
PLT  Platelets 
TFT  Thyroid function tests 
TG  Triglyceride 
THS  Thyroid-stimulating hormone 
U&E  Urea and electrolytes 
WBC  White blood cell count 
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First draft Care Plan 




PHARMACEUTICAL CARE PLAN: MENTAL HEALTH 
PATIENT PROFILE 





  CHI # Gender 
  
Male       
 
Female   
Social History 




















Date of birth/ Age Weight
/ kg 
 












































Use of illicit drugs   
                                    Y      





Alcohol consumption  
                                     Y     
                                     N     



























RELEVANT MEDICAL HISTORY 
Date (approximate) Problem description Date (approximate) Problem description 
    
    
    
    
    
 
RELEVANT DRUG HISTORY / ADVERSE EVENT HISTORY  
Date (approximate)                                                 Medication                                                                                        Comments 
   
   
   
   
   
   
   
 
 
RELEVANT PSYCHIATRIC HISTORY 
 

























Care Episode 1 
Date:  
Values               Date 
Care Episode 2 
Date: 
Values               Date 
Care Episode 3 
Date: 
Values               Date 
Care Episode 4 
Date: 
Values           Date 
Care Episode 5 
Date: 
Values               Date 
Care Episode 6 
Date: 
Values               Date 
Weight (kg)                        
Blood pressure             
Creat (55–120) µmol/l             
Na     (135-145)mmol/l             
K           (3.5-5) mmol/l             
Ca   (2.12-2.65)mmol/l             
Urea  (2.5-6.7) mmol/l             
ALT        (5-35)      µ/l             
GGT     (7-33) F     µ/l 
           (11-51) M    µ/l 
            
Bili        (3-17)  mmol/l             
FBC                  x 10
9
/ l             
WCC     (4-11)  x 10
9
/ l             
Hb  (11,5-16) F     g/dl     
        (13,5-18)M    g/dl 
            
Gluc  (3.5-5.5) mmol/l             
Chol  (3.9-7.8) mmol/l             
Tg    (0.55-1.9) mmol/l             
CPK (25-170) F    IU/l 
         (25-195) M   IU/l     
            
TSH (age related)              
Free T4  (9-22) pmol/l             
Prolactin    <600 F  
U/l 
                   <450 M  
U/l 
            






Regular medication Dose Route Administration times Stop 
date 
Comments 
8 1 6 10 other 
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
Start 
date 
Depot Injections Dose Frequency Stop 
date 
Comments 
      
      
      
      
AS REQUIRED MEDICATION 
Start 
date 










         
         
         
         





HIGH DOSE ANTIPSYHOTICS 
Date Percentage calculated from BNF Drugs / Doses 
   
   
   
   
 
 
TERAPEUTIC DRUG MONITORING 
Medication Date Dose Hours post dose Concentration Target 
concentration 
Comment 
       
       
       
       
       
 
 
  Care issue check list? 
 







Patient Education / Documentation 
Changes and Therapeutic Plan Checks 
Therapeutic Plan Changes 
(Individualisations/ Dosage change/  Treatment interruption/ 
Management of co-morbidity) 








Output                     
(Initial) 
 








Output                     
(Initial) 
 









Output                     
(Initial)  
 










Output                     
(Initial)  
 










Output                     
(Initial)  
 








Output                     
(Initial) 
 








Output                     
(Initial) 
 










Output                     
(Initial)  
 








Output                     
(Initial) 
 










Output                     
(Initial)  
 







Output                     
(Initial)  
 














The Development of a Pharmaceutical Care Plan in the Scottish Mental Health Service 
118 
 










Changes to the first draft care plan; 
Issues raised by research group and suggestions followed 
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Discussion point Research group suggestions Done 
Lay out Remove some of the data fields , to compress the care plan   
Patient details,  
 
Leave Social history blank.   
Remove number a day and ex-smoker from smoking status-box   
Change “use of illicit drugs” to “substance misuse   
Admission details, 
remove some unimportant 
data fields , to  compress 
the care plan 
Merge date and source of admission   




Merge planned and actual discharge   
Remove tick boxes for close monitoring drugs   
Relevant medical history Add compliance   
Decrease space for date   
Relevant drug history / 
ADR history 
Split table in two identical sections   
Add OTC / complementary needs in a box below   
Relevant psychiatric 
history 
Lose five lines   
Monitoring / 
investigations 
Divide lab-investigations into themes    
Remove Care episodes   
Change gluc to FBG (fasting blood glucose), and move it    
Supply with HDL, LDL, and PLT and neutrophiles    
Use REH reference range   
Current medication Remove administration times   
Add non-psychotropic- and psychotropic medication   
High dose 
antipsychotics 
Change headings to date, dose, BNF %, and monitoring episodes   
Therapeutic drug 
monitoring 
Change headings to date, medication, dose, time of sample, 
concentration measured and range  
  
Split table in two identical sections   





Remove week number   
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Prototype Care Plan 
Before field testing  




PHARMACEUTICAL CARE PLAN - MENTAL HEALTH 







CHI # Gender 
 
Male         
Female     
 
Family History Social History 
Age / 















































Date and Source 










Discharge Date Advanced   Y 
Statement   N 






RELEVANT MEDICAL HISTORY (INCLUDING HISTORY OF NON-COMPLIANCE) 
Date  Description Date Description 
    
    
    
RELEVANT DRUG HISTORY (INCLUDING ADVERSE OR NON RESPONSIVE THERAPY)                                                     
Date Medication Comments Date Medication Comments 
      
      
      
      
      
      














PHARMACIST’S MONITORING REVIEWS 
Date               
Sign              
CLINICAL MONITORING 
Date             
Weight (kg)                        
Blood pressure             
Creat        (60–120) µmol/l             
Na            (135-145)mmol/l             
K                  (3.6-5) mmol/l             
Ca              (2.1-2.6)mmol/l             
Urea         (2.5-6.6) mmol/l 
FBG         (3.5-5.8) mmol/l 
            
            
ALT                  (10-50) µ/l             
GGT                   (5-55) µ/l              
Bili              (3-16)  mmol/l             
WCC          (4-11)  x 10
9
/ l             
Platelets (150-350) x 10
9
/ l             
Neutrophils (2-7.5) x10
9
/ l             
Hb                  (11-18)  g/dl             
Chol         (3.9-7.8) mmol/l             
HDL      0.9-1.4 mmol/l (M) 
              1.1-1.7 mmol/l (F) 
            
LDL      3.0-6.4 mmol/l (M) 
             2.8-6.1  mmol/l (F) 
            
TG          (0.55-1.9) mmol/l             
CPK         (25-170) F    IU/l 
                (25-195) M   IU/l     
            
TSH               (age related)              
Free T4         (9-22) pmol/l             
Prolactin         <600 F  U/l 
                        <450 M  U/l 





           
 
RECORD OF MONITORING FOR HIGH DOSE ANTIPSYCHOTIC PRESCRIBING 
Start 
Date 
Medication Dose BNF % Evidence of Monitoring 
 if performed  
Stop 
date 
















       
THERAPEUTIC DRUG MONITORING 











            
            
            
            








Y      
















        
        
        
        
        
        
        
        
        
        
        
        
        
        
Start 
date 
Non- Psychotropic  
Medication 





        
 
 
      
        
        
        
        
        
        
        










       
       
       
       
AS REQUIRED MEDICATION 
Start 
date 










         
         
         
         
         
         
         
          
STANDARD CHECK’S IDENTIFYING PROBLEMS WITH; 
1.Drug history       3.Guidelines      5.Interactions     7.HD antipsychotics  9.Compliance                    
2.Polypharmacy   4.DTP risk         6.ADR’s             8.MHA T2/T3             10.Patient understanding  
            
INDIVIDUALISED CARE ISSUES 
Date Care 
Issue 
Therapeutic Plan Checks + 
Documentation Changes + Patient 
Education 
Therapeutic Plan Changes 
(Individualisations/ Dosage Change/  Treatment Interruption/ 
Management of Co-morbidity) 






































































































































































































Y      
















        
        
        
        
        
        
        
        
        
        
        
        
        
        
Start 
date 
Non- Psychotropic  
Medication 





        
 
 
      
        
        
        
        
        
        
        










       
       
       
       
AS REQUIRED MEDICATION 
Start 
date 










         
         
         
         
         











Care plan guidance text 




Guidance for the completion of the 
Mental Health Pharmaceutical Care Plan 
 
Patient details, admission details 
Complete as soon as possible after admission. 
 Note the patient‟s name, address, postcode, 
date of birth (age) and CHI number. If a patient 
label with all this information is available, it 
should be applied here. 
 Provide the names and, if known, the addresses 
of the Carer, GP and community pharmacy. If 
you find that there are other community persons 
that are more important to record, feel free to 
change as you write. 
 Note the general patient characteristics 
including gender, weight, height and BMI (if 
available)  
 Note smoking status and substance misuse e.g. 
alcohol, illicit drugs (specify what is being 
misused)  
 Record any known drug sensitivities. 
 Use the general comment box to record other 
things you find important to have documented 
e.g. Patient‟s social- and family history  
 
Relevant Medical History / Compliance 
Note relevant medical history you find useful, e.g. 
diabetes, cardiovascular problems etc.  
Include if the patient has a history of 
treatment/medication non-compliance. 
 
Relevant Drug History / ADRs 
Note patient response to any earlier treatments, if 
he/she had a satisfactory/ unsatisfactory response, 
had any unwanted/adverse effects from medication 
etc.  
 
Purchased Medicines/ Complementary 
Treatments 
Note any medicine that the patient takes without 
prescription i.e. Over The Counter medication, 
including herbs and vitamins of interest. E.g. St. 
Johns Wort (hypericum). Also any other treatments 
that might be considered complementary 
 
Relevant Psychiatric History 
Extract the key data, and record information you 
consider useful to have available at a glance - do not 
replicate a full psychiatric history. 
 
Pharmacist Reviews 
Note the date lab results were checked, and sign.   
 
Clinical Monitoring Abnormality 
Record any abnormal values of the relevant 
laboratory results and the dates they were taken. 


















High Dose Antipsychotic Medication 
 Note the date the antipsychotic prescribing 
became „high dose‟.  
 Calculate and note the percentage (High) dose 
of each antipsychotic drug from the 
recommended daily dose as indicated in the 
BNF.  
Confirm necessary monitoring has been performed 
as per High Dose prescribing Guidelines every 3 
months by making a √ under evidence of monitoring 
preformed.  
 
Therapeutic Drug Monitoring 
Note time and date that the sample was taken. This 
will allow accurate calculation of plasma levels 
according to the number of hours post/pre dose.   
Record the measured concentration and 
recommended plasma range of the drug. 
 
Current Medication 
Record regular psychotropic, including depot and 
other long acting injectable formulations, and non 
psychotropic medication separately.  (Non 
psychotropic includes all medication that is NOT 
related to the mental condition of the patient). Also 
record „as required‟ medication (prn) in the box 
provided. When a drug has been discontinued it 
might be a good idea to make a red line over it. 
Fill in the administration times using whatever format 
you find most useful 
 
Standard check’s 
Ten categories of standard check‟s are listed as a 
check procedure for the patient screening process. If 
a check has led to identification of an individualised 
care issue you should tick the box that best describes 
the care issue. Care issues should be numbered 
according to the standard check category.  
 
Individualised Care Issues 
Report Care Issues arising from the routine 
monitoring in the patient‟s individualised care plan. If 
the care issues has been numbered from the 
standard check‟s, the number should be recorded in 
the “date and no” column.  
The column on the left is for all specific checks and 
all changes that are directed at correcting the patient 
records or addressing educational needs.  
The column on the right is used to separate out the 
treatment changes. If a check leads immediately to a 
treatment change, the care issue should be 
documented in terms of the change. For example a 
check of creatinine leading (in the same care 
episode) to a change in dose should be recorded as 
a dose change plus explanation together in the right 
hand column. See example 
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Example care plan 
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PHARMACEUTICAL CARE PLAN - MENTAL HEALTH 











Male         
Female     
 
Comments (e.g. Family and Social History) 
 
Lives with wife, no children 
 Age /   53 yr 
Date of birth 
20.06.54 
Address 
19/3 Forth Street 
Edinburgh 
 
Postcode  EH1 3LE 
Weight / kg 
80 kg 






















Tel 111 5678 




















Yes   No  
Specify: 
ADMISSION DETAILS 
Admission;  Arranged by CPN at 14.04.2006      
Date and Source   
Date/ Legal Status 
14.04.06 / STDC 
Presenting Complaint 
 












Advanced   Y 
Statement   N 






RELEVANT MEDICAL HISTORY (INCLUDING HISTORY OF NON-COMPLIANCE) 
Date  Description Date Description 
Okt 
2004 
Diabetes type 2. Diet controlled   
June 
2005 
Hypertension   
    
RELEVANT DRUG HISTORY (INCLUDING ADVERSE OR NON RESPNSIVE THERAPY)                                                     
Date Medication Comments Date Medication Comments 
1991 Haloperidol Acute dystonic reaction    
2002 Citalopram Sexual dysfunction    
4/6–07 Valproate Dose dependent tremor    
 Mirtazapine Relapse episode    
 Phenelzine Relapse episode    
 Reboxetine Works    





RELEVANT PSYCHIATRIC HISTORY 
Date Description 
1991 Psychotic illness – drug induced? 
1993 BPAD – manic episode. Admission for 3/12.  
Okt.1996 Anxiety disorder. 10 session input from psychologist 
1999-2006 BPAD – hypomanic episodes in 1999, 2001, 2005 and 2006. Admitted for about 2/12 every time. 




PHARMACIST’S MONITORING REVIEWS 
Date 15/4 21/4 29/4            
Sign ms ms ms            
CLINICAL MONITORING ABRORMALITY 
Date      14/4        21/4        28/4               
Weight (kg)             
Blood pressure             
Creatinine          (60–120) µmol/l             
Na                      (135-145)mmol/l             
K                            (3.6-5) mmol/l             
Ca                        (2.1-2.6)mmol/l             
Urea                    (2.5-6.6) mmol/l             
Blood glucose     (3.5-5.8) mmol 11,1 6 4,2          
ALT                            (10-50)  µ/l             
GGT                              (5-55) µ/l              
Bilirubin               (3-16)  mmol/l             
WCC                      (4-11)  x 10
9
/ l             
Neutrophils            (2-7.5) x10
9
/ l              
Platelets           (150-350) x 10
9
/ l             
Hb                            (11-18)  g/dl             
Chol esterol       (3.9-7.8) mmol/l             
HDL             
CPK                   (25-170) F    IU/l 
                           (25-195) M   IU/l     
            
TSH (age related)              
ECG             
             
             
             
             
             
             
             
 
RECORD OF MONITORING FOR HIGH DOSE ANTIPSYCHOTIC PRESCRIBING 
Start 
Date 
Medication Dose BNF 
% 
Evidence of Monitoring 




















       
THERAPEUTIC DRUG MONITORING 











25/4-06 Valproate 1g, bd 8 pm 
(12h 
post) 
110 mg/l 50-100 
mg/l        
            
            








Y      




















OD     
14/4-




06   
        
20/4-
06 Valporate m/r 
1 g O Nocte 22/4-
06   
22/4-




06   
24/4-
06 Valporate m/r 
1 g O BD 26/4-
06   
25/4-
06 Quetiapine 
50 mg O BD 26/4-
06  Increase by 50 mg a day until 200 mg, BD 
26/4-
06 Valporate m/r 
900 
mg O 





BD    
        
        
        
        
        
        
        
Start 
date 
Non- Psychotropic  
Medication 









20 mg O OD    
 
 
      
        
        
        
        
        
        
        
        
AS REQUIRED MEDICATION 
Start 
date 












Haloperidol 5mg O agitation 1hour 30mg 18/4-
06  
         
         
         
         
         
         
         
         
 
STANDARD CHECK’S IDENTIFYING PROBLEMS WITH; 
1.Drug history    3.Guidelines        5.Interactions     7.HD antipsychotics  9.Compliance                      
2.Polypharmacy 4.Co-morbidity    6.ADR’s             8.MHA T2/T3             10.Patient understanding    
 






Therapeutic Plan Checks + 
Documentation Changes + Patient 
Education 
Therapeutic Plan Changes 
(Individualisations/ Dosage Change/  Treatment Interruption/ 











Risk of EPSE due to Haloperidol , (Patient has history of 





Need for Haloperidol prn to be discussed with prescriber 

















Check with patient/ GP to restart usual treatment – lisinopril 
20 mg 












Specify Note interaction between valproate and 
lamotrigine. Lamotrigine levels may double, 
however been on this combination before 





Monitor  for s/e particularly rash 
 
 
Output                       















Patient c/o tremor.  








Reduce dose slightly, and reassess tremor 
 
Output                       
 





















Atypical antipsychotic options discussed.  
UKPPG leaflets provided. 
 
Start on quetiapine 
Output                     Patient agreed to quetiapine for hypomania, 
largely as a result of its evidence for use in 
bipolar depression (NICE) 
Responding well to combination, continue treatment short 
term 
 
